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 CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Cancer occurs when cells lose control of their growth due to the abnormal activation 
of signaling cascades that mediate cell proliferation. Ras proteins are one of the key 
regulators that control cell growth, proliferation, and differentiation [1], and mutations in Ras 
proteins are found in multiple human tumors [2].  
As a monomeric, guanine nucleotide binding protein, Ras switches between its GTP 
bound, activated form and its GDP bound, inactivated form. Ras proteins are highly 
homologous to one another and differ only in their C-termini, which serve as membrane 
anchors. All Ras isoforms are post-translationally modified by addition of the farnesyl group. 
N-Ras, H-Ras, and K-Ras4A are acylated with one (for N-Ras and K-Ras4A) or two (for 
H-Ras) palmitoyl groups, whereas K-Ras4B carries a polybasic amino acid sequence in its 
C-terminus instead [3].  
Originally, the plasma membrane (PM) was thought to be the only platform from 
which Ras signaling occurs. At the plasma membrane, Ras is able to interact with multiple 
downstream signaling partners, which ultimately leads to cell proliferation and survival. 
Among the many Ras signal transduction cascades that take place at the plasma membrane, 
two of the most studied cascades are the mitogen-activated protein kinase (MAPK) pathway 
and the phosphatidylinositol-kinase (PI3K)-AKT pathway. Cell proliferation is usually 
associated with activation of the MAPK signaling pathway, whereas cell survival is usually 
associated with activation of the AKT/PI3K pathway [4, 5].  
The plasma membrane can be further compartmentalized into two subdomains, “raft” 
and “non-raft,” based on size, composition, and formation [6]. A membrane raft is often 
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described as a membrane domain that is enriched in cholesterol and sphingolipid [6, 7]. Ras 
proteins are distributed both in the membrane rafts and bulk plasma membrane [8–11]. How 
Ras proteins initiate signals within these subdomains on the plasma membrane and whether 
these different domain locations are essential to the Ras downstream signaling and biological 
functions are still underdetermined [12].  
Much of the research data for the past few years suggest that—in addition to the 
plasma membrane—Golgi, ER, and endosomes also serve as signaling platforms for Ras 
[13]. Because different signaling output of Ras is dependent on the spatial organization of the 
Ras proteins and the regulators of Ras within the cell, learning how Ras is targeted to 
different cellular compartments may give us valuable insights into the activation of Ras 
mediated signal transduction and, ultimately, to Ras induced tumorigenesis. A few studies 
have suggested that H-Ras protein may distribute to the intracellular compartments through 
the de-acylation/re-acylation cycle [14] and K-Ras could be directed there through 
phosphorylation [15] or calmodulin/glutamate dependent manner in particular cell types [16, 
17]. However, the entire mechanism of how Ras proteins are allocated to the endosomes is 
not known. Moreover, the kind of endosomes to which Ras binds has not been determined.  
In this research presented in this dissertation, my colleagues and I utilized several 
DNA constructs of Ras variants and Arf6 GTPase and expressed the correspondent Ras and 
Arf6 proteins in mammalian cells. We isolated the cell membranes and characterized the 
protein localizations by subcellular fractionation, immunoisolation, density gradient 
centrifugation, and detergent treatment. We detected the Ras proteins and their signaling 
cascades by Western blots. We also examined the plasma membrane and intracellular 
localization of Ras proteins by immunofluorescence and studied the biological activity of 
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cells expressing Ras proteins through microscopy. Through these methods, we characterized 
a type of endosomes where H-Ras is localized and thereby identified a new 
clathrin-independent pathway through which membrane bound H-Ras can allocate to the 
intracellular membranes. We also found that both of the plasma membrane microdomains, 
raft and non-raft, allow H-Ras signaling and biological activity. These findings not only 
enrich our current understanding of trafficking, signaling, lipid modifications, membrane 
locations, and cell functions of Ras, but also suggest new directions for future research.  
Thesis Organization 
This dissertation follows the journal paper format described by the Graduate College 
and is comprised of four chapters. The first chapter gives an overview of Ras proteins and 
their signal transduction cascades. The following two chapters are manuscripts resulting from 
research conducted in the lab of Dr. Janice Buss at Iowa State University and will be 
submitted for publication. The first manuscript, Clathrin-independent endosomes assocaiated 
with Arf6 bind both active and inactive forms of H-Ras, describes a new mechanism through 
which H-Ras allocates to endosomal membranes. The second manuscript, Biological activity 
and signaling of H-Ras variants designed to be preferentially “in” or “out” of rafts, presents 
the results of a study of two H-Ras variants that are preferentially localized on raft or non-raft 
domains of the plasma membrane. The final chapter is a general discussion of the results and 
the conclusions drawn from them. 
Author’s Contributions 
I am one of the two first coauthors of the Chapter 2 manuscript, Clathrin-independent 
endosomes assocaiated with Arf6 bind both active and inactive forms of H-Ras. I performed 
biochemical studies to determine which endocytosis pathway (clathrin-dependent or 
 4
clathrin-independent) H-Ras utilizes. In order to do this, I immunoisolated EEA-1 and 
conducted the immunofluorescence studies to check the plasma membrane and intracellular 
locations of EEA-1, clathrin, MHC-I, and H-Ras (as seen in Fig. 1 [except Fig. 1E], Fig. 2 
[A, A', A", B, B', and B"]). I examined what class of endosomes H-Ras binds by 
immunoisolation of the Arf6 endosomes (as seen in Fig. 3). I also checked whether one of the 
H-Ras effectors, Raf-1, is located on the Arf6 endosomes (as appeared in Fig. 5). 
Additionally, I examined the endocytosis of K-Ras by testing whether K-Ras4B is present on 
the perinuclear endosomal recycling center (ERC) and whether C-terminal domain of 
K-Ras4B proteins targets GFP to the Arf6 endocytic pathway (data can be seen from Fig. 7B 
and Fig. 8B). Moreover, I organized and edited all figures for this manuscript.  
I am the first author of the Chapter 3 manuscript, Biological activity and signaling of 
two H-Ras variants designed to be preferentially “in” or “out” of rafts. My major 
contribution to this paper was characterizing the signaling transduction pathways of two 
H-Ras variants that are predicted to be localized to the raft and non-raft domains of the 
plasma membrane (data as seen in FIG. 7–9). I determined the membrane locations of these 
Ras variant proteins by immunofluorescence (data as shown in FIG. 2, FIG. 5A, and FIG. 6). 
My colleagues and I also determined the membrane locations of these Ras variant proteins by 
density gradient (data as shown in FIG. 4A). I organized and interpreted the data from other 
researchers in our lab and prepared this manuscript. 
Literature Review 
General Ras proteins and their basic properties 
Ras is a member of small GTPase superfamily proteins. As GTPases, Ras proteins 
share a principal biochemical activity of GTP binding and hydrolysis. Ras proteins switch 
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between the active, GTP bound (“on” position) state and the inactive, GDP bound (“off” 
position) state. Oncogenic mutations of Ras take place in the GTP/GDP binding regions. 
These mutations impair the GTP hydrolysis activity and stabilize the Ras GTP binding state 
and thus lead Ras to have a high binding affinity with its downstream effectors [18, 19]. 
The first Ras gene was identified and characterized as an oncogene in the Harvey and 
Kirsten strains of acutely transforming retroviruses [20, 21]. Mutationally activated forms of 
H-Ras, K-Ras, and N-Ras were subsequently isolated from human tumor cells. Overall, an 
activating mutation of one of the Ras genes has been found in about 20% of all human 
tumors [22], with high frequencies seen in cancers that have poor survival rates and limited 
therapeutic options, including cancers of the pancreas, thyroid, and lung [2].  
The Ras proteins are highly homologous in the first 85% of their amino acid 
sequence, including the guanine nucleotide and effector-binding regions [23]. The remaining 
C-terminal sequence, which consists of residues 166-185, is known as the hypervariable 
(HVR) domain. The HVR is highly divergent with the exception of the last four amino acids, 
the CAAX motif, where a cysteine is followed by two aliphatic residues and one serine or 
methionine [24]. The CAAX motif directs a series of posttranslational modifications 
including lipidation with polyisoprene for many prenylated proteins [25]. 
Post-translational modification of Ras proteins 
After synthesis, Ras proteins are farnesylated in the cytoplasm by the farnesyl 
transferase that attaches a farnesyl group to the cysteine residue of the CAAX motif [26] 
(Figure 1). Next, the farnesylated Ras proteins translocate to the endoplasmic reticulum 
where the AAX tripeptide is removed by an endopeptidase, Ras converting enzyme 1 (Rce1). 
Following the cleavage of the AAX, the carboxyl-terminal farnesyl cysteine is methylated by 
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isoprenylcysteine carboxyl methyltransferase (Icmt) [27, 28]. H-Ras, N-Ras, and K-Ras4A 
further undergo palmitoylation on cysteine residues near the C-terminus and travel to the 
plasma membrane (PM) via ER and Golgi [29–31]. Newly synthesized H-Ras also utilizes a 
Golgi-independent mechanism to traffic to the PM [32]. K-Ras4B does not have a 
palmitoylated cysteine in the hypervariable domain; it contains multiple lysine residues 
instead that also help it associate with plasma membrane. Unlike H-Ras, K-Ras4B is targeted 
to the plasma membrane through a Golgi-independent mechanism, which is currently not 
understood. The trafficking of K-Ras4B to the plasma membrane may be directed by 
microtubules [33] or operated by the electrostatic gradient [33, 34].  
Ras effectors and signaling cascades 
Activation of Ras proteins leads to activation of Ras downstream effectors. These 
effectors include, but are not limited to, protein and lipid kinases like Raf and PI3kinase, 
guanine-nucleotide exchange factors (GEFs) for other Ras superfamily members. Activated 
Ras proteins can initiate and activate many downstream signaling cascades by recruiting 
these effectors (Figure 2).  
Even though there are many signal transduction cascades that are mediated by Ras, 
the best understood among these is the mitogen-activated protein kinase (MAPK) pathway. 
The MAPK pathway contains at least three kinases—Raf, MEK, and ERK—which transmit 
signals though sequential phosphorylation procedures. The Ras mediated Raf-MEK-ERK 
activation pathway is a pathway that can cause cell transformation. In order for Ras to initiate 
the MAPK signal transduction cascade, Ras must bind to the “Raf-like Ras-binding domain” 
and the nearby cysteine-rich domain of the Ras effectors, the serine/threonine protein kinase 
Raf-1 (also named c-Raf) or A-Raf and B-Raf to active Raf-1 kinase [35, 36]. Raf-1 kinase 
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phosphorylates and activates mitogen-activated protein kinases 1 and 2 (MEK1 and MEK2). 
After MEK1 and MEK2 are activated, they phosphorylate the downstream mitogen-activated 
protein kinases (MAPKs) ERK1 and ERK2 (extracellular signal-regulated kinases 1 and 2). 
The activated ERK proteins can translocate to the nucleus, where they phosphorylate their 
majority of their substrates, transcription factors, and thus lead to a change in gene 
expressions. Activated ERKs also phosphorylate other substrates that are found in the cytosol 
and in other cellular organelles [37]. The activation of ERK1 and ERK2 mediates many 
cellular activities including cell proliferation, differentiation, mitosis, and apoptosis [37, 38]. 
The Ras-Phosphatidylinositol 3 kinase (PI3K)-AKT pathway is another 
well-established Ras signaling pathway. In this pathway, activated Ras binds to the p110 
catalytic subunit of PI3 kinase, a Ras effector. The interaction between Ras and PI3 kinase 
increases the production of phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3, which is 
localized on the cell membrane, binds to the PH domain containing protein kinases such as 
AKT (also known as PKB), and thereby recruits AKT to the plasma membrane. AKT can 
then be activated on the PM by phosphorylation. Activated AKT phosphorylates its 
downstream substrates such as BAD protein, transcription factor CREB, and thereby 
regulates multiple biological processes including glucose metabolism, apoptosis, and 
tumorigenesis [39, 40]. 
Another downstream signaling cascade occurs when activated Ras recruits MEK 
(MAPK kinase) kinase (MEKK)[41–43], another Ras effector, which can activate the JNK 
kinase (JNKK) [44–46] . JNKK1 (also called MEK4) and JNKK2 (also called MEK7) 
activate their downstream c-Jun NH2 terminal kinase (JNK) by phosphorylating the 
Thr-Pro-Tyr phosphorylation sites of JNK [47]. Activated JNK in turn phosphorylates its 
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downstream substrates—such as transcription factors including c-Jun, p53, ATF-2, Elk-1 and 
the nuclear factor of activated T cells (NFAT)—and thereby regulates the related gene 
expression that leads to cell growth, differentiation, or apoptosis [38]. JNK2 is required for 
H-Ras mediated transformation [48]. 
The Ras guanine-nucleotide exchange factors (GEFs) catalyze the release of GDP and 
thus promote the loading of GTP and Ras activation (Figure 2). The three main kinds of Ras 
GEFs are Sos, Ras-GRF, and Ras GRP. They all share a common CDC25 homology and an 
adjacent Ras exchange motif [49]. 
Unlike GEFs, p120Gap, a GTPase activating protein (GAP) negatively regulates Ras 
GTPase (Figure 2). It catalyzes the hydrolysis of bound GTP from Ras by a mechanism 
involving stabilizing the transition state of GTP hydrolysis through an arginine finger loop 
and thus negatively regulates the GTPase [50]. 
The various isoforms of Ras may interact with their effectors and activate their 
downstream cascades differently, resulting in differences in biological activity. For example, 
activated H-Ras is more relevant to the activation of the PI3 kinase pathway, whereas 
activated K-Ras is more relevant to the activation of the Raf-1 pathway than H-Ras [51]. 
K-Ras is essential for mouse embryogenesis, whereas N-Ras and H-Ras knockout mice show 
no apparent abnormalities [52, 53]. A recent study also indicates that K-Ras has a unique role 
in cardiovascular homeostasis [54]. These differences in effector activation and biological 
activity may be due to the distinct cellular microenvironments in which these different 
isoforms of Ras proteins can be localized [55–58].  
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Ras signaling on endomembranes 
Ras proteins have been shown to be distributed on endomembranes as well as on the 
plasma membrane. Ras proteins can also signal from endomembranes such as the Golgi 
apparatus, ER, and mitochondria [59, 60]. Upon EGF stimulation, Ras becomes activated 
both on the PM and the Golgi in fibroblasts [61]. N-Ras also demonstrates strong activation 
in Golgi in T cells [62]. Studies have also shown that mitochondria associated 
phospho-K-Ras 12V181E can induce apoptosis through a pathway that requires Bcl-XL [15]. 
Different compartmentalization of Ras also moderates different signaling outputs. 
Recent studies used H-Ras constructs that are fused to different intracellular tethering 
domains to study the signaling in the defined sublocations [61, 63]. The results demonstrated 
that activated H-Ras that was tethered to the KDEL receptor showed strong activation of both 
the AKT and ERK pathways but weak activation of JNK [63]. On the other hand, H-Ras 
targeted to the ER by the avian bronchitis virus M1 showed robust activation of JNK but 
weak activation of AKT and ERK [61, 63]. Thus, the subcellular location of Ras seems to 
influence Ras signaling outputs. 
General endocytosis and endosomal trafficking 
In eukaryotic cells, proteins and lipids are transported along the endocytic pathways. 
In the endocytic pathways, molecules are internalized from the PM and then directed into 
sorting endosomes where they can either continue on to the endocytic recycling 
compartments and then return to the PM or travel to late endosomes and lysosomes for 
degradation. 
Cells can take up nutrients and internalize particles through endocytosis. In 
mammalian cells, endocytosis has an essential role in delivering receptors and their 
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associated ligands, membrane domains and proteins, and soluble molecules to the destination 
organelles. Endocytosis is classified into two broad categories: phagocytosis (cell eating) and 
pinocytosis (cell drinking) [64]. Phagocytosis, which involves uptake of large particles, is 
restricted primarily to specialized cells such as macrophages. On the other hand, pinocytosis 
is found in all cells. There are at least four distinct pinocytosis mechanisms: 
macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated endocytosis, and 
clathrin-independent endocytosis [64, 65]. 
Of the four types of pinocytosis mechanisms, clathrin-dependent endocytosis is the 
best understood. Molecules such as low-density lipoprotein (LDL), LDL receptors, 
transferrin (Tfn), and transferrin receptors all use clathrin-mediated endocytosis [66–68]. 
Formation of clathrin-coated vesicles begins when triskelions assemble into a polygonal 
lattice at the plasma membrane and form clathrin-coated pits. Next, clathrin-binding adaptors 
such as adaptor protein-2 (AP2) directly bind to clathrin and initiate the budding and 
pinching of coated pits from the PM in a dynamin-dependent manner [64]. Other adaptors 
such as epsins and phospholipids (i.e., phosphatidylinositol-4, 5-biphosphate [PIP2]) are also 
found in coated pits and facilitate budding of clathrin-coated vesicles [68, 69].  
In contrast to the clathrin-coated vesicular mechanism, clathrin-independent 
endocytosis is not well understood. Major Histocompatibility Complex I (MHCI) [70], Arf6 
GTPase [70–72], CD59 [73], E-cadherin [74], integrins [71, 75], and interleukin-2 (IL-2) 
receptors on lymphocytes [76] are all thought to be internalized through clathrin-independent 
mechanisms. Although there are multiple categories of non-clathrin endocytosis, this type of 
endocytosis can be further categorized into dynamin-GTPase dependent and 
dynamin-GTPase independent. 
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After being internalized into the cytosol, clathrin-coated vesicles are uncoated before 
they fuse with the sorting endosomes [69]. The sorting endosomes are rich in 
phosphatidylinositol-3-phosphate (PI3P) and some unique FYVE-domain proteins, such as 
EEA-1 and rabenosyn-5, both of which are required for the fusion of the sorting endosomes 
[77]. After sorting, receptors can be directed to endocytic recycling compartments and then 
to the cell surface, or they can be directed to the multivesicular elements that resemble the 
endosomal carrier vesicles/multivesicular bodies (ECV/MVBs) and then to late endosomes 
and lysosomes for degradation [77]. The non-clathrin pathway can deliver molecules to 
multiple intracellular compartments such as the Golgi [78, 79], as well as to the classical 
endocytic endosomal compartments such as the endocytic recycling compartment [80]. The 
clathrin pathway can also target molecules to the Golgi [81] or from the Golgi to the 
endosomes [68]. 
Endosomal locations and retrograde trafficking of Ras proteins 
The plasma membrane, where Ras proteins undergo repeated cycles of 
activation/inactivation and signaling, has been considered the final destination for Ras. 
Traditionally, Ras was thought to be post-translationally modified and trafficked via 
ER/Golgi to the plasma membrane. Although H-Ras and N-Ras proteins can be found on the 
Golgi apparatus, the Ras proteins were thought to be just passing through the Golgi on their 
way to reach their final destination on the PM. However, recent studies have provided direct 
evidence that the plasma membrane association of different Ras proteins can be dynamic 
instead of static. H-Ras proteins appear to be endocytosed as part of their normal function in 
propagating signals from activated cell surface receptors [82]. Ligand activated epidermal 
growth factor receptors (EGFR) are rapidly internalized by clathrin-coated pits and delivered 
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to early endosomes where they are sorted to internal endosomal vesicles for degradation or 
recycled back to the plasma membrane [83, 84]. Upon insulin or NGF stimulation, Ras and a 
complete MAPK signaling complex can also be found on the intracellular vesicular complex 
containing endosomes [85–87]. Signaling of H-Ras to Raf-1 is also reported to be dependent 
on endocytosis [88]. These results indicate that endosomal trafficking of H-Ras and Raf 
appear to be critical for growth factor stimulated MAPK activation in these cells and that Ras 
may not reside on the plasma membrane permanently.  
A recent study [14] shows that de-palmitoylation/re-palmitoylation of H-Ras and 
N-Ras may contribute to the redistribution of Ras between the Golgi and the plasma 
membrane. The de-palmitoylated Ras can dissociate from the plasma membrane and be 
released to the cytosol, where it can be randomly captured at the Golgi apparatus and 
re-palmitoylated again (Figure 3) [14]. Thus H-Ras and N-Ras can traffic backwards from 
the PM to the Golgi by the de-palmitoylation/re-palmitoylation cycle. Jura, Scott-Lavino, 
Sobczyk, and Bar-Sagi [89] showed that H-Ras but not K-Ras can be ubiquitinated, and this 
modification promotes H-Ras’ association with endosomes. Recent studies showed that the 
GTP-bound form of H-Ras can be endocytosed in the cells overexpressing Rab5 proteins 
[88], and its return to the plasma membrane is dependent on the endosomal-recycling 
pathway [90]. Thus, H-Ras not only can internalize from the PM but also can recycle back to 
the PM as well (Figure 3). As for K-Ras, in rat hippocampal neurons upon glutamate 
stimulation, K-Ras can be released from the plasma membrane through binding with the 
Ca2+/calmodulin at the C-terminus of K-Ras [16]. Recently, K-Ras was also found 
dissociated from the plasma membrane and distributed on the mitochondria through the 
phosphorylation of serine 181 within the C-terminal polybasic region by protein kinase C 
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[15]. These findings suggest that partially neutralizing the positive charge of the polybasic 
sequence will discharge K-Ras from the PM, but whether or how K-Ras is recycled back to 
PM is undetermined. Moreover, the precise mechanism of how Ras proteins localized on 
endosomes and the completed machinery of Ras retrograde trafficking remains to be 
determined. 
Membrane rafts and Ras microdomain locations 
The plasma membrane of mammalian cells is a heterogeneous mixture comprised of 
hundreds of proteins and lipid species. Based on the observed data, researchers have 
proposed hypotheses to define the structure of the plasma membrane more precisely. A 
widely accepted hypothesis of the membrane structure is the “membrane raft” hypothesis. 
The most contemporary definition of rafts [91] states that “ Membrane rafts are small  
(10–200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched domains that 
compartmentalize cellular processes. Small rafts can sometimes be stabilized with one 
another to form larger platforms though protein-protein interactions.” Membrane rafts are 
rich in saturated phospholipids and cholesterol, are tightly packed and ordered, and have less 
fluidity than the surrounding plasma membrane. In contrast, “non-raft” membranes are poor 
in cholesterol, rich in unsaturated phospholipids, and have more fluidity [6]. For this reason, 
membrane rafts are also defined as liquid ordered lipid domains separated from liquid 
disordered domains [92, 93]. Because of their relatively compact structure, membrane rafts 
are poorly solubilized by common nonionic detergent such as Triton X-100 at 4oC. The 
membrane raft fractions isolated according to this biochemical property are found to be rich 
in cholesterol and sphingolipids but often poor in glycerolphospholipids, and to accumulate 
glycosylphosphatidylinositol (GPI) anchored proteins, sphingomyelin, and gangliosides as 
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well as other specific proteins such as acylated proteins; [92, 94]. This specific composition 
enables membrane rafts to serve as platforms for protein segregation and cellular signaling 
[95]. 
The heterogeneity of plasma membranes in turn leads to the nonrandom 
microorganization of lipid anchor proteins that are located on the PM. With regard to 
micro-locations of Ras proteins, most of the research has been done by the John Hancock 
group, who used several methods including electron microscopy (EM) and fluorescent 
recovery after photo bleaching (FRAP). For the micro-location of H-Ras, their work 
indicated that the GDP bound form of H-Ras is mainly associated with cholesterol-dependent 
(rafts) microdomain, while the GTP bound form of H-Ras is associated with the cholesterol-
independent (non-raft) microdomain [55, 96]. They suggested that the hypervariable region 
(HVR) and the different position of palmitoylated residues of the H-Ras C-terminus 
contribute to the lateral segregation of H-Ras on raft and non-raft domains [11, 55, 97]. Up to 
now, the data indicating how the HVR of N-Ras affects the mircrodomain location of N-Ras 
is not available. N-Ras, however, is found to be located on the non-raft domain, but localized 
to rafts when it is activated [11]. Both K-Ras-GDP and K-Ras-GTP are found to be located in 
the non-raft domains of the plasma membrane [11]. The farnesyl motif seems to play a major 
role in distributing K-Ras into the non-raft membrane and many farnesylated proteins are 
sequestered in non-raft membrane microdomains [98–101]. The polybasic region of K-Ras 
also plays an important function of localizing K-Ras to the plasma membrane through the 
interaction with acidic lipids, for example, phosphatidylinositol-1, 4, 5-triphosphate (PIP3), 
and phosphatidylinositol-4, 5-biphosphate (PIP2) on the plasma membrane [102].  
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Recent membrane studies by a fluorescence resonance energy transfer (FRET) 
examination indicated that GPI anchored proteins, which are raft protein markers, are 
organized in nanoscale (<5 nm), as nanoclusters on the plasma membrane [103]. This 
nano-domain is enriched with proteins and is also dynamic. FRAP studies from Kenworthy 
group demonstrate that both K-Ras and H-Ras diffuse quickly on the plasma membrane, 
indicating that either these microdomains are quite mobile or the associations of Ras proteins 
with these domains are very dynamic [104]. Using single fluorophore video tracking (SFVT), 
Murakoshi et al. [105] showed that during mitogen activation, the diffusion of the H- and 
K-Ras proteins on the PM decreased and the fractions of immobilized Ras proteins increased 
. Moreover, the immobility of Ras proteins is not affected by cholesterol depletion, which is a 
characteristic of non-raft membrane. New experimental data and computer modeling showed 
that K-Ras nanoclusters operate as a “sensitive digital switch,” a graded system which 
responds to varied doses of EGF stimulation for MAPK signaling [106]. These studies 
advance our understanding of how Ras proteins and their associated microdomains are 
organized with regard to signaling. 
Summary 
Ras traffics and signals from different intracellular locations including the PM, ER, 
Golgi apparatus, and endosomes. Ras is localized on the cellular membrane and can also be 
distributed on the different microdomain locations of that membrane. The different 
trafficking routes and sub-cellular locations of the Ras may influence the Ras signaling 
ability, specificity, and the biological function of the cell in which Ras is expressed. 
Therefore, it is important to know where, when, and how Ras signaling is initiated and 
regulated. Enhanced knowledge of the complexity of Ras signaling and the regulation 
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mechanisms might allow further understanding of carcinogenesis and provide clues for 
cancer therapies to be designed to inhibit specific signaling pathways activated by Ras 
proteins. 
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Figure Legends 
Figure 1. Processing of Ras proteins. The Ras processor proteins are first farnesylated in 
the cytosol by farnesyl transferase (FTase). Processing is completed in the ER by 
the enzyme Rce1 which removes the –AAX residues followed by 
carboxyl-methylation on the farnesylated cysteine residue by enzyme Icmt. H-Ras 
and N-Ras further undergo palmitoylation by the palmitoyl transferase (PAT) and 
transport to the plasma membrane (PM) via Golgi. H-Ras also utilizes a 
Golgi-independent mechanism to traffic to the PM. K-Ras, which cannot be 
palmitoylated, is targeted to the plasma membrane through an unclear, 
Golgi-independent mechanism.  
Figure 2. Major Ras signaling cascades. Illustration of three major signaling cascades of 
Ras proteins. Guanine nucleotide exchange factors (GEFs) stimulate displace 
GDP, resulting in increased level of Ras-GTP. GTP bound Ras can interact 
productively with more than 20 effectors including Raf, phosphatidylinositol 
3-kinase (PI3K), and MEKK to regulate various cellular responses such as 
proliferation, survival, and gene expression. Ras signaling is terminated by 
 30
hydrolysis to Ras-GDP, and this reaction is catalyzed by the GTPase-activating 
proteins (GAPs). 
Figure 3. Endocytosis and trafficking map of Ras. Ras signaling is widely shown on the 
plasma membrane. Ras proteins have reported to be distributed and signals from 
internal membranes such as ER and Golgi. Ras proteins are also found on vesicles 
with all the characteristics of endosomes. Plasma membrane bound H-Ras and 
N-Ras can traffic from the PM to the Golgi through the de-palmitoylation 
/re-palmitoylationcycle. 
Figures
Figure 1 
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CHAPTER 2. CLATHRIN-INDEPENDENT ENDOSOMES 
ASSOCIATED WITH ARF6 BIND BOTH ACTIVE AND  
INACTIVE FORMS OF H-RAS 
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Abstract 
H-Ras that becomes de-palmitoylated at the plasma membrane can relocate through a 
cytosolic intermediate to internal sites. H-Ras has also been sighted on endocytic vesicles and 
recently on recycling endosomes, but the class of endosomes to which it bound has remained 
uncharacterized. The aims of this study were to identify those endosome(s), to examine 
whether inactive or active forms of H-Ras bound different endosomes, and to determine 
which endosomes could bind active H-Ras-GTP or the Ras effector, Raf-1. The results 
showed that oncogenic H-Ras61L, or normal H-Ras (in either basal or EGF-stimulated NIH 
3T3 cells), were absent from endosomes of the clathrin-associated pathway. Instead, both 
forms of H-Ras were present on endosomes of the clathrin-independent Arf6-associated  
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pathway and in the endosomal-recycling center. In contrast, Raf-1 was distributed primarily 
on separate EEA1-containing endosomes of the clathrin-dependent path. Arf6-associated 
vesicles could also bind K-Ras4B-12V or chimeric green fluorescent proteins with either 
H-Ras or K-Ras4B C-termini. However, neither K-Ras4B nor the chimeric GFP-K-tail 
proteins were present in the endosomal-recycling center. These results identify 
Arf6-associated endosomes as a specific class of constitutive endosomal vesicles that can 
bind both active and inactive H-Ras proteins and that provide a second platform, in addition 
to Golgi membranes, for membrane-bound H-Ras to localize on intracellular membranes.  
 
Key words: protein trafficking, perinuclear recycling center, endocytosis, endosome, 
Arf6, clathrin, EEA1, Raf-1, Ras  
Introduction 
Although the site of Ras signaling is widely depicted as the plasma membrane, Ras 
proteins have now been shown to be distributed on, and to produce significant signals from, 
internal membranes [1–3]. The means by which Ras proteins localize to these internal sites 
are varied and not fully characterized. In neurons, calcium signals trigger Ca++/calmodulin 
binding to K-Ras4B and cause the release of the K-Ras/calmodulin complex from the plasma 
membrane [4]. This transient, cytosolic complex is subsequently targeted to Golgi and 
recycling endosomes [5]. For H-Ras, a small portion [6] of the newly synthesized protein is 
delivered to Golgi membranes, and from there boards outward-bound exocytic vesicles  
[7, 8]. Recent work indicates that if palmitoylated H-Ras that is already at the plasma 
membrane becomes de-palmitoylated, it is released into the cytosol, and then can be 
re-palmitoylated and thus captured on internal membranes from which it can then rejoin the 
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biosynthetic pathway [9]. However, H-Ras has repeatedly been found on vesicles with all the 
characteristics of endosomes [10–12], including new observations of H-Ras on membranes of 
the pericentriolar endocytic recycling compartment [13]. A small portion of H-Ras can also 
become ubiquitinated, a modification that stabilizes its association with endosomes but that 
seems to decrease its association with Golgi membranes [14]. It is unclear whether H-Ras 
that reaches the plasma membrane must await depalmitoylation before it can re-enter the cell 
and bind to internal membranes or whether a membrane-bound form of H-Ras can traverse 
the cytosol and serve as a source for membrane-based intracellular signaling.  
A clear identity for the endosomes to which H-Ras binds has not been reported. There 
is even the possibility that more than one type of endosomal pathway might be utilized, as 
the distribution of H-Ras in the plasma membrane is reported to vary. The inactive form of 
H-Ras is included in raft-like lipid microdomains, while GTP-bound forms inhabit the more 
general lipid bilayer [15]. Endocytic pathways also show preferences for one type of domain 
or the other [16]. A previous study has shown that a Rab5- and dynamin-regulated pathway 
of endocytosis and recycling is required for signaling by the Ras effector, Raf-1 [17]. 
Additional studies report that both Rab5 and Rab11 regulate H-Ras trafficking to the 
pericentriolar recycling center [13]. However, Rab5 is found on endosomal membranes and 
sorting endosomes that are derived from both clathrin-mediated and clathrin-independent 
pathways [13, 18], and thus does not define a specific class of endosomes. Expression of the 
constitutively active Rab5-Q79L protein causes some H-Ras to accumulate on enlarged 
endosomes, but, notably, not Raf-1 [19]. Thus, the portion of H-Ras that binds those 
endosomes appears to disengage from this effector. Raf-1 itself has also been observed on 
endosomes, co-localizing with EEA1, an early endosomal marker for the clathrin-mediated 
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pathway [11]. Other studies report that blocking clathrin-mediated endocytosis with a 
dominant, mutant form of epsin or AP180 does not prevent accumulation of H-Ras on 
intracellular membranes [2, 9]. In addition, in earlier electron microscopy studies, H-Ras was 
notably absent from clathrin-coated pits or flat arrays on the plasma membrane [15, 20, 21]. 
Although these studies suggested that H-Ras could leave the plasma membrane and enter an 
endocytic pathway, they did not provide a clear identity for that pathway or answer whether 
activated H-Ras could maintain its GTP-bound state while on such endosomes. 
Several pathways for clathrin-independent endosomal entry of proteins have been 
described [16, 18, 22–25, 56]. One of these is a pathway that serves as an entry route for the 
class I major histocompatibility complex protein (MHC-I), the IL-2 receptor subunit, the 
beta-1 subunit of integrins, and the Src tyrosine kinase [26–28]. This pathway is identifiable 
by the presence of Arf6. Arf6 is a member of the Arf and Arl subfamily of small GTPases 
that participate in vesicular trafficking [29]. Although many Arf GTPases localize primarily 
on internal membranes, the Arf6 protein is located on the plasma membrane, endosomes, and 
tubular-vesicular recycling membranes [30]. Several studies suggest that Arf6-associated 
vesicles converge on the endosomal recycling center (ERC) [31], where they mingle among 
other endosomes that are derived, independently, from clathrin-mediated endocytosis [27, 
32]. Arf6-associated vesicles also participate in a recycling pathway that returns proteins to 
the plasma membrane [33, 34]. 
The studies reported here examined what type(s) of endosomes could bind H-Ras and 
its effector, Raf-1. The results build a new mechanistic link between Arf6 and H-Ras that 
reaches from the plasma membrane to the perinuclear endosomal recycling center, and 
complete a framework for a new itinerary of H-Ras movements within the cell. 
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Material and Methods 
Plasmids, cell culture and DNA transfection  
The H-Ras and Ext-Ras DNAs in the pcDNA3 vector were described previously [35]. 
GFP-H-Ras-61Q, GFP-K-Ras4B-G12V, GFP-Ext-Ras61L, GFP-Ext-Ras-61Q, and 
GFP-H-Ras-61L were constructed using the pcDNA3 versions as PCR templates and 
transferred to the pEGFP-C3 vector (Clontech Labs). GFP-RBD contains the “Ras binding 
domain” residues 51–131 of Raf-1 [2] that were transferred to pEGFP-C3 from a cDNA for a 
GST-RBD that was obtained from the laboratory of Dr. C. Der (University of North 
Carolina). GFP-H-tail was constructed by attaching the bases encoding the 10 C-terminal 
amino acids of H-Ras (GCMSCKCVLS), a termination codon, and a Bam H1 restriction 
enzyme site to pEGFP-C3 by PCR. Arf6-67Q-GFP (Arf6-WT, wild type) and 
Arf6-Q67L-GFP are in the pEGFP-N1 vector; Arf6-67Q-HA and Arf6-Q67L-HA each with 
a C-terminal hemagluttinin (HA) epitope tag, are in pXS vectors. Dr. J. G. Donaldson, 
National Institutes of Health, generously provided all the Arf6 constructs and the GFP-K-tail 
plasmid in which the last 20 residues of K-Ras4B are attached to the C-terminus of EGFP.  
NIH 3T3 cells were cultured at 37°C and 10% CO2 in Dulbecco’s modified Eagle’s 
medium supplemented with 10% calf serum plus penicillin, streptomycin, glutamine, and 
sodium pyruvate. For immunofluorescence and immuno-isolation, NIH 3T3 cells were 
transfected with Effectene (Qiagen) according to the manufacturer’s instructions and used 
after 24 hours or as mentioned in the results. The H-Ras61L or H-RasWT (HRas cellular 
form, wild-type) stable cell lines have the H-Ras61L or H-RasWT DNAs expressed from the 
pZIPneo vector; the GFP-H-Ras61L stable cell line has the GFP-H-Ras61L DNA expressed 
from the pEGFP-C3 vector. Cells treated with EGF (Gibco BRL) were cultured in the same 
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media described above and incubated with 5 or 10 ng/ml of EGF at 37°C for the time as 
indicated, followed by washing with phosphate-buffered saline and fixation. 
Antibodies 
Antibodies used for immunoblotting included mouse monoclonal anti-Ras (BD 
Bioscience 610010), mouse monoclonal anti-c-Raf (BD Bioscience 61051), rabbit polyclonal 
anti-hemagluttinin (Covance PRB-101P), mouse monoclonal anti-GFP (Roche 1814460), and 
rabbit polyclonal anti-EEA1 (ABR P1-063). For immunofluorescence, rat monoclonal 
anti-Ras (sc-34), rabbit polyclonal anti-c-Raf-1 (sc-227), and rabbit polyclonal anti-clathrin 
heavy chain (sc-9069) were from Santa Cruz Biotechnology. Mouse monoclonal antibody 
(W6/32) to human MHC-I protein was from Leinco Technologies (#H263). Antibody to the 
cis-Golgi protein, giantin was from Covance. For the experiment in Fig. 4, primary antibody 
is mouse monoclonal anti-Ras (BD Bioscience 610010). The same EEA1 antibody or mouse 
anti-hemagluttinin (Covance PRB-101R) were used for both immuno-isolation and 
immunofluorescence. Murine monoclonal anti-Ras (Quality Biotech LA069) and the above 
rat monoclonal anti-Ras antibody are also used for immuno-isolation. Secondary antibodies 
from Molecular Probes included goat anti-mouse IgG coupled to Alexa Fluor 350, goat 
anti-rat IgG coupled to Alexa Fluor 488, goat anti-mouse IgG coupled to Alexa Fluor 594, 
goat anti-rabbit IgG coupled to Alexa Fluor 594, donkey anti-rat IgG coupled to Alexa Fluor 
594, and transferrin from human serum coupled to Alexa Fluor 594. 
Live cell labeling with transferrin or MHC-I antibody 
To mark early endosomes of the clathrin-dependent pathway, cells were transfected 
and incubated for 18 hours, then cycloheximide (10 µg/ml) was added for 5.25 hours to allow 
time for previously synthesized protein to vacate Golgi membranes. Cells were then chilled 
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for 45 minutes at 4°C in a cold room in medium containing 50 mM HEPES, pH 7.4 buffer, 
cycloheximide (10 µg/ml), and AlexaFluor-transferrin (Molecular Probes, 10 µg/ml). Finally, 
the cold medium was removed and prewarmed (37°C) medium containing 50 mM HEPES, 
pH 7.4 was added and cells were incubated at 37°C in a water bath for one minute before 
fixation with cold 4% paraformaldehyde and processing for immunofluorescence. 
For marking the endosomal recycling center (ERC), cells were transfected with 
various cDNAs, incubated for 18 hours, and then treated for 5.25 hours with cycloheximide 
(10 µg/ml). AlexaFluor-transferrin (10 g/ml) was then added for 45 minutes. Cells were 
washed, fixed, and processed for immunofluorescence. 
To monitor MHC-I internalization, HeLa cells were transfected and incubated for 18 
hours, then cycloheximide (10 µg/ml) was added for 5.5 hours to allow time for newly 
synthesized H-Ras proteins to vacate Golgi membranes. Cycloheximide-containing media 
with MHC-I antibody (200 µg/ml) was equilibrated to 37o C and then added to the above 
cells for 30 min at 37o C. At the end of incubation, cell surface-associated antibodies were 
removed by rinsing the cells in low pH solution (0.5% acetic acid, 0.5M NaCl, pH 3.0) for 30 
seconds [27]. Cells were fixed with 4% formaldehyde in phosphate-buffered saline (PBS) for 
10 minutes, permeabilized, and stained in blocking buffer (2% horse serum, 0.4% bovine 
serum albumin, and 0.2% saponin in PBS, pH 7.4) [27, 36]. The internalized antibodies were 
visualized with the appropriate fluorochrome-labeled secondary antibody in the above 
blocking buffer. 
Immuno-isolation of membranes 
Twenty-four hours after transfection, cells were scraped into 300 µl homogenization 
buffer (3 mM imidazole, pH 7.4, 1 mM Na3VO4, 5 mM MgCl2, 1% Protease Inhibitor 
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Cocktail (Sigma), and 5% sucrose) and homogenized with 15 strokes in a Dounce 
homogenizer followed by 20 passages through a 26-gauge needle. The nuclei and unbroken 
cells were removed by centrifugation at 1300 x g (4 °C) for 10 minutes. This post-nuclear 
supernatant (PNS) was pre-cleared by incubation for one hour at 4°C with protein G- or 
protein A-agarose beads (Invitrogen). Beads were removed, and the supernatant was then 
incubated with mouse monoclonal anti-HA antibody or a mixture of mouse and rat 
monoclonal anti-H-Ras antibodies or rabbit EEA1 antibody overnight. The following day 
fresh protein G agarose beads (or protein A beads for rabbit EEA1 antibody) were added for 
two hours at 4°C. The beads were washed three times in cold homogenization buffer and 
boiled in SDS-PAGE sample buffer. Proteins present in the membranes were separated by 
SDS-PAGE and detected on immunoblots with the indicated antibodies. Then 95% of the 
sample was loaded in the IP lane and 5% in the PNS lane. 
Immunoblotting  
Samples collected by immuno-isolation were separated by SDS-PAGE. Proteins were 
transferred to polyvinylidene difluoride (PVDF) membranes (Pall Life Science) and then 
incubated in blocking buffer (Vector Labs 10x casein diluted to 1x ) in TTBS (0.15 mol/L 
NaCl, 0.05 M Tris-HCl, 0.05% Tween-20, pH 7.4]) for 20 minutes at room temperature. 
PVDF membranes were washed in TTBS and incubated with primary antibodies overnight at 
4°C. The proteins of interest were detected using horseradish peroxidase-conjugated goat 
anti-mouse or goat anti-rabbit secondary antibodies and an enhanced chemiluminescence kit 
from Pierce. 
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Immunofluorescence and preparation of sonicated membrane fragments 
NIH 3T3 cells were plated on coverslips coated with 100 g/ml poly-L-lysine (Sigma) 
and 500 g/ml fibronectin (Sigma) and transfected with DNA. After 24 hours (or as mentioned 
in the results), cells were fixed with fresh 4% formaldehyde in phosphate-buffered saline, pH 
7.4, at room temperature for one hour then permeabilized with -20°C methanol and quenched 
with 50 mM ammonium chloride in phosphate-buffered saline. The fixed cells were 
incubated with blocking buffer (2% horse serum and 0.4% bovine serum albumin in 
phosphate-buffered saline, pH 7.4), then sequentially with primary and secondary antibodies 
diluted in blocking buffer. For the experiment shown in Fig. 4D, cells were cotransfected 
with cDNAs for H-Ras61L and Arf6-Q67L-GFP. Both proteins were expressed in >90% of 
the transfected cells (data not shown). Cells were fixed and stained with mouse anti-Ras (BD 
Bioscience 610010) and Raf antibody. The Ras antibody was detected with a goat anti-mouse 
IgG secondary antibody coupled to AlexaFluor350 (blue), and its co-expression in each cell 
that expressed the Arf6 protein was visually confirmed, but blue images were not captured.  
Experiments to produce adherent plasma membrane fragments were carried out 
exactly as described previously [37]. The slips were mounted in Vectashield mounting 
medium (Vector Laboratories). For experiments imaging adherent membrane fragments, 
cells were analyzed using a 60x oil immersion lens on a Nikon Eclipse E800 microscope 
with Spot RT digital camera. All the confocal images were taken with a Leica TCS-NT 
confocal system with a 63x oil immersion lens with an aperture adjustable from 1.32 to 0.6, 
using an argon laser (488 nm excitation) and a krypton laser (568 nm excitation). Other 
images were taken with Leica DMIRE2 microscope using a 100x oil immersion lens with an 
aperture adjustable from 1.3 to 0.6 and Q Imaging Retiga 1300 camera. Images were 
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exported to Adobe Photoshop 7.0; the images taken with the Leica DMIRE2 microscope 
were taken in black and white, processed in Openlab3.5.1, displayed in colors, and then 
exported to Adobe Photoshop 7.0 to equalize image intensity prior to merging. For some 
experiments, as indicated in the figure legends, a series of z-stack images were acquired 
using a motorized stage on the Leica DMIRE2 microscope. These images were processed 
using Openlab’s nearest neighbor deconvolution module and processed as above. 
Results 
H-Ras does not bind endosomes of the clathrin-dependent pathway 
The previous report of the dynamin sensitivity of H-Ras-triggered Raf-1 signaling 
[17] suggested that H-Ras might be found on endosomes of the dynamin-sensitive, 
clathrin-dependent pathway. To inspect specifically only plasma membranes for possible 
H-Ras and clathrin co-localization, adherent basal plasma membranes of transfected NIH 
3T3 cells were prepared by sonication, fixed, and examined by indirect immunofluorescence 
[37]. However, neither the activated H-Ras61L (Fig. 1A) nor the transfected cellular form of 
H-Ras (H-Ras-WT; data not shown) overlapped with clathrin heavy chain.  
Another marker of a later step in the clathrin-dependent pathway—the early 
endosome antigen-1 protein (EEA1)—was used to determine if H-Ras was present in early 
endosomal vesicles that had already lost their clathrin coat. Upon examination of 
EEA1-positive vesicles in intact cells, no overlap of H-Ras-WT and EEA1 was detected (Fig. 
1B). On adherent fragments of basal membranes from sonicated cells, the population of 
EEA1-positive vesicles was more clearly resolved, but again no H-Ras (this time the 
activated form, H-Ras61L) was present in these vesicles (Fig. 1C). Because EEA1 marks 
early endosomal vesicles specifically, these results indicated that neither an oncogenic nor 
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the normal form of H-Ras were present on early endosomes derived from the 
clathrin-dependent pathway. 
Because the experiments with H-Ras61L used a permanently activated, mutant form 
of H-Ras, we also tested if H-Ras-WT that became transiently GTP-bound after EGF 
stimulation now joined the clathrin-dependent pathway. This was a relevant question, as the 
serum-activated form of H-Ras is reported to shift from raft-like lipid microdomains, to a 
more general membrane distribution from which clathrin-mediated internalization might 
occur [15]. However, after stimulation of cells for 10 minutes with a moderate, 10 ng/ml dose 
of EGF [38], no co-alignment of the EEA1 marker of early endosomes and H-Ras-WT was 
detected (Fig. 1D).  
As an additional test, a fluorescent derivative of transferrin was added to live cells to 
enable tracking of the first minutes of clathrin-mediated endocytosis. For these experiments, 
a cycloheximide pretreatment was included to avoid imaging newly synthesized H-Ras on 
Golgi-derived vesicles that might mingle with the endocytic vesicles. Cells were then chilled 
and incubated with transferrin, so as to label, but prevent internalization of, transferrin 
receptors. Cells were warmed briefly (one minute) to allow internalization to restart. 
Although H-Ras-positive vesicles were present in the rewarmed cells, the 
transferrin-containing early endosomes did not overlap with GFP-H-Ras61L (Fig. 1E). Thus, 
although H-Ras was present on vesicles, it was notably absent from endosomes associated 
with these characteristic steps of the clathrin-dependent endocytic route. 
To supplement the previous imaging results, we used a biochemical approach to 
examine if H-Ras in its GTP-bound form might be present on EEA1-containing endosomes. 
Using an antibody to EEA1 and a detergent-free protocol for immuno-isolation of membrane 
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fragments and vesicles [11], the presence of H-Ras and endogenous Raf-1 on 
EEA1-containing endosomes was assessed. In agreement with the imaging results, neither 
cellular H-Ras nor activated H-Ras61L (Fig. 1F) could be detected on the captured EEA1-
containing membranes.  
Thus, by multiple techniques, we found no evidence of H-Ras on endocytic vesicles 
that were derived from the clathrin-dependent pathway. 
In spite of this absence, endogenous Raf-1 was easily observed in these EEA1 
antibody-captured endosomes (Fig. 1F). This ability to capture a protein that did associate 
with EEA1-containing membranes verified that the membrane isolation protocol was 
successful, and thus validated the absence of H-Ras on those membranes. This result 
confirmed previous work that Raf-1 could be found on EEA1-containing early endosomes 
[11]. All these studies indicated that endosomes to which H-Ras was bound had not entered 
the cells via a clathrin-mediated pathway. 
Endosomes associated with Arf6 bind H-Ras 
A prominent class of non-clathrin plasma membrane structures is comprised of 
caveolae. However, the ability of caveolae to internalize (as “caveosomes”) is generally 
thought to be restricted to special situations such as viral infection [39]. H-Ras, although 
present on membranes with a low buoyant density similar to that of caveolae, is largely 
absent from these structures [15, 37]. Thus another class of non-caveolar, 
clathrin-independent endosomes for binding H-Ras was sought. 
An additional type of clathrin-independent endosomes is those which arise from the 
constitutive pathway by which the endogenous major histocompatibility complex I (MHC-I) 
is internalized [31]. To examine this pathway, endosomal vesicles containing MHC-I were 
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identified by applying an antibody that recognizes an external epitope of human MHC-I to 
live HeLa cells. In addition, to further diminish the signal from endogenous MHC-I and 
transfected GFP-H-Ras that were within the biosynthetic pathway, cycloheximide was added 
to the transfected cells for the final six hours before fixation. Anti-MHC-I antibody was 
added to the culture medium for the last 30 minutes to label MHC-I at the cell surface. Cells 
were then briefly washed with mild acid to remove MHC-I antibody that had not entered the 
cell, were fixed, and then were stained with secondary antibody for the internalized MHC-I 
antibody [36, 40]. The resulting images showed multiple vesicular structures that held both 
GFP-H-Ras (Fig. 2A and A”) and endogenous MHC-I protein (Fig. 2A’ and A”), as well as 
other vesicles that held only a single protein.  
MHC-I is reported to traffic through a pathway that is associated with the Arf6 small 
GTPase [41, 42]. The extent of co-localization of externally labeled MHC-I with an 
expressed Arf6-Q67L tagged with GFP was therefore examined. Similar to the study with 
H-Ras and MHC-I, there were multiple vesicles that contained both Arf6-Q67L-GFP (Fig. 
2B and B”) and MHC-I (Fig. 2B’ and B’’), and others that held only a single protein. These 
results implied that H-Ras should be present on vesicles on which Arf6 was located. To test 
this prediction, NIH 3T3 cells were co-transfected with H-Ras-WT and a GFP-tagged version 
of the cellular form of Arf6 (Arf-WT-GFP), and were examined by fluorescence microscopy. 
H-Ras-WT (Fig. 2C) was observed on the plasma membrane, as expected, and also on both 
small endosomes and larger, apparently fluid-filled, pinosomes that were also populated by 
Arf6-WT-GFP (Fig. 2C’). Arf6 is often associated with pinosome structures [43]. At high 
resolution (in a separate cell), the Arf6 and H-Ras proteins appeared to inhabit adjacent but 
distinct domains of many of the larger endosomes, producing a beaded appearance in cross-
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section (Fig. 2D). After acute expression, constitutively active H-Ras61L was also present on 
Arf6-associated endosomes (data not shown). These results agree with the previous finding 
that endogenous Ras proteins can be found on endosomes regardless of their activation state 
[11]. Long-term expression of activated H-Ras61L causes oncogenic transformation and also 
stimulates pinocytosis [10]. To learn if the complex cellular changes that accompany 
transformation might alter H-Ras61L binding to Arf6-associated endosomes, a cell line that 
stably expressed H-Ras61L was transfected with cDNA encoding Arf6. In these transformed 
cells, endosomes marked by the Arf6 protein still carried the oncogenic H-Ras61L (data not 
shown).  
These results indicated that endosomes that contained Arf6 could bind H-Ras in both 
the GDP- and GTP-bound states. This data provided a complement for the earlier 
biochemical experiments that indicated that neither H-Ras-WT nor H-Ras61L nor 
EGF-stimulated H-Ras-GTP bound clathrin-dependent endosomes. 
To examine if Arf6 activation changed the ability of these endosomes to bind H-Ras, 
an Arf6 protein that favors the GTP-bound form (Arf6-Q67L) was used. The Arf6-Q67L 
protein supports the early steps of endosome formation in a normal fashion, but the inability 
of the protein to hydrolyze its bound GTP prevents the nascent endosomes from further 
progress, leading to an endocytic cul-de-sac and formation of multiple, enlarged endosomes 
[30]. In cells that co-expressed Arf6-Q67L-GFP and H-Ras61L, the distinctive groups of 
large, Arf6-Q67L-GFP endosomes (Fig. 2E and E”) were brightly outlined by the H-Ras61L 
protein (Fig. 2E’ and E”). Thus, endosomes in which the Arf6 protein was GTP-bound could 
also bind H-Ras. 
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To further characterize these endosomes, cells were transfected with a hemagluttinin 
(HA)-tagged version of Arf6-Q67L-HA along with GFP-H-Ras61L so that Arf6-containing 
membranes could be immuno-isolated using HA antibody. On these isolated, detergent-free 
fragments of Arf6-HA-containing membranes, GFP-H-Ras61L was present (Fig. 3A). A 
reverse experiment, using H-Ras-directed antibody capture, showed that Arf6-Q67L-GFP 
could also be detected on H-Ras-containing membrane fragments (Fig. 3B). In addition, a 
control experiment, in which anti-HA antibody-directed membrane isolation was performed 
using cells that expressed GFP-H-Ras but that had no Arf6-HA to capture, showed that no 
GFP-H-Ras was present in the HA-antibody-captured sample (Fig. 3C). This indicated that 
the presence of H-Ras in the sample required Arf6, and was not the result of incomplete 
membrane washing or non-specific binding of H-Ras to the HA antibody.  
EGF stimulates GTP binding to H-Ras on Arf6 endosomes 
Given the constitutive nature of endocytosis via the Arf6-associated pathway, an 
important issue was whether binding to these endosomes would result in rapid down 
regulation of H-Ras GTP binding. This question had not been answered by the previous 
experiment with H-Ras61L, because H-Ras61L GTP hydrolysis is impaired. This experiment 
required a cell to simultaneously express 3 proteins: Arf6, H-Ras-WT, and GFP-RBD (a 
GFP-tagged version of the Ras binding domain of Raf-1 that would bind to and report the 
location of the GTP-bound form of H-Ras). To accomplish this with only two color filters, 
the activated Arf6-Q67L was used so that its presence could be detected by the distinctive 
clustering of endosomes it produced, rather than by staining. The triply transfected cells were 
then either left untreated or were exposed to a low concentration of EGF for varying times 
before fixation and imaging. 
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In untreated cells, the H-Ras-WT protein, in its basal, GDP-bound state, outlined the 
plasma membrane and the clustered, Arf6 endosomes (Fig. 4A), as before, while the 
GFP-RBD was nearby in the cytosol (Fig. 4A’). This is the appropriate cytoplasmic location 
for GFP-RBD in an unstimulated cell. After five minutes of exposure of the cells to EGF, 
GFP-RBD (Fig. 4B’) could now be seen both at the plasma membrane and on many 
H-Ras-WT-coated, enlarged endosomes (Fig. 4B). Notably, within this short time frame, no 
significant binding of GFP-RBD to perinuclear membranes that might be Golgi was observed 
[44]. This result indicated that H-Ras-WT could become GTP-bound at the plasma 
membrane and on Arf6-associated vesicles that were already internal, or on endosomes that 
had entered the cell during the five minutes of EGF exposure. 
Previous studies had shown that total H-Ras GTP binding remains elevated for 
several minutes after EGF stimulation, and returns to baseline within about one-half hour 
[12]. Similarly, in this experiment, after 10 minutes of exposure to EGF, GFP-RBD remained 
visible on both the plasma membrane and on many Arf6-Q67L vesicle membranes (Fig. 4C). 
Thus, during EGF stimulation, H-Ras continued to associate with, and retained GTP while 
bound to, Arf6 vesicles. There was no indication that endosomal H-Ras lost GTP more 
rapidly than H-Ras at the plasma membrane. After 30 minutes of EGF exposure, GFP-RBD 
binding to the plasma membrane and to Arf6 vesicles, did decline, indicating that H-Ras GTP 
binding had dropped (data not shown). These results indicated that vesicles of the 
Arf6-associated endocytic pathway did not initiate rapid down regulation of H-Ras activity. 
Very little Raf-1 binds to H-Ras61L on Arf6 endosomes 
The initial studies described above had indicated that early endosomes that contained 
EEA1 did not bind H-Ras, but did bind the H-Ras effector protein, Raf-1. The finding that 
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Arf6-associated vesicles harbored GTP-bound H-Ras raised the question of whether some 
Raf-1 might also be present on Arf6-coated vesicles. Because Arf6 is present both on the 
plasma membrane (where Raf-1 is known to associate with active H-Ras) and on endosomal 
membranes, immunofluorescence was used so that Arf6 endosomes could be examined 
specifically, rather than immuno-isolation from a mixture of membranes. Cells were 
co-transfected with DNAs for Arf6-Q67L (to generate visibly identifiable endosomes) and 
GFP-H-Ras61L, then were stained with antibodies for endogenous Raf-1. As before, the 
characteristic Arf6-Q67L vesicles and clustered endosomes were brightly rimmed with 
GFP-H-Ras61L (Fig. 5A and B). However, the Raf-1 antibody did not illuminate those 
clustered endosomes (Fig. 5A’ and B), and in only a few spots did endogenous Raf-1 and 
H-Ras61L co-localize on endosomes. As expected, however, some endogenous Raf-1 did 
co-localize with H-Ras61L at the plasma membrane (Fig. 5C). A second experiment was 
performed to examine more directly whether the smaller endosomes that displayed 
transfected Arf6-Q67L-GFP could bind Raf-1. Cells were transfected with cDNAs for 
H-Ras61L and Arf6-Q67L-GFP, and cells that expressed both proteins were identified (data 
not shown [see Immunofluorescence Methods]). In these cells, presumptive vesicular forms 
of endogenous Raf-1 were visible, but very few of the dots of endogenous Raf-1 aligned with 
dots of the Arf6, or with the clustered, larger, Arf-Q67L-stimulated endosomal structures 
(Fig. 5D). These results further suggested that Arf6 endosomes bound very little Raf-1 
despite harboring an activated H-Ras61L.  
H-Ras is present in the perinuclear endosomal recycling center 
Although some H-Ras is present on Golgi membranes, recent studies have found that 
H-Ras persists in the perinuclear area despite clearing the H-Ras biosynthetic pathway by 
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exposing cells to cycloheximide [8, 9]. Our own studies (see below) confirmed that even 
after prolonged interruption of biosynthesis, H-Ras was present (i.e., either retained or 
continuously replaced) on perinuclear membranes. One source of this internal H-Ras is from 
previously synthesized protein that was de-palmitoylated at the plasma membrane and that 
recycles through the cytoplasm until it is re-palmitoylated and recaptured on 
endomembranes. The potential for an additional contribution of endosomal pathways, and in 
particular the perinuclear endosomal recycling center (ERC), to the internal pool of H-Ras 
was investigated.  
In order to specifically distinguish the ERC from Golgi membranes, transferrin, a 
protein known to enter the ERC area (via the clathrin-mediated route), was used. In cells 
pretreated with cycloheximide for six hours, live-cell uptake of AlexaFluor-transferrin for 45 
minutes at 37°C produced a strong perinuclear accumulation of transferrin in the ERC, along 
with numerous peripheral transferrin-laden vesicles that were traversing the cytoplasm (Fig. 
6A’). In these cycloheximide-treated cells, the previously synthesized H-Ras61L (Fig. 6A) 
that was located on internal membranes co-localized entirely with the perinuclear 
concentration of AlexaFluor-transferrin, and not with a marker of the cis-Golgi, giantin (Fig. 
6B andC). Transfected H-RasWT also co-aligned well with the transferring-marked ERC 
(data not shown). This indicated that the internal membranes populated by previously 
synthesized H-Ras were predominantly those of the ERC, and that, with this protocol, very 
little H-Ras was located on Golgi membranes. This data supported the recent report that 
H-Ras is associated with Rab11-positive vesicles in the recycling center [13]. Notably, at the 
periphery of the cell, the previously synthesized GFP-H-Ras61L was present in small 
vesicles that were separate from those that contained AlexaFluor-transferrin (Fig. 6D and E). 
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This corroborated the results shown above indicating that H-Ras61L could bind vesicles that 
were separate from those that carried transferrin. The ERC region was too densely packed 
with vesicles to determine if the H-Ras-containing vesicles simply intermingled or actually 
merged with transferrin-containing vesicles. These results indicated that, in addition to Arf6-
associated endosomal membranes and membranes of the Golgi, H-Ras could distribute to a 
third type of internal membrane—the membranes of the ERC. 
K-Ras4B and Ext-Ras binding to Arf6 endosomes differs from H-Ras 
The route of the outward, biosynthetic trafficking of the non-palmitoylated K-Ras4B 
protein is unknown, but appears to differ from the vesicular mechanism used occasionally by 
H-Ras [6]. We therefore examined if these two Ras proteins also differed in their presence on 
Arf6-associated vesicles or the ERC. An activated GFP-K-Ras4B-12V protein could be 
clearly seen on the plasma membrane and on Arf6-Q67L-enlarged endosomes (Fig. 7A and 
A’). This result indicated that Arf6-associated vesicles could also bind activated K-Ras4B, 
and that this form of Ras was not excluded from this pathway. However, when the ERC was 
marked, by loading cells with AlexaFluor-transferrin (without Arf6-Q67L), activated 
K-Ras4B could not be seen in the ERC (Fig. 7B). Thus, K-Ras4B differed from H-Ras and 
did not bind either ERC or Golgi membranes.  
To learn more about the properties that were responsible for the binding of Ras 
proteins to Arf6 endosomes, an H-Ras protein with C-terminal characteristics of both H-Ras 
(palmitates) and K-Ras4B (lysine residues) was examined [35]. This protein (Ext-Ras) is a 
version of H-Ras with a C-terminal extension of six lysines that act to prevent attachment of 
farnesyl. Because of its lack of farnesylation, Ext-Ras also fails to undergo proteolysis or 
methylation and does not interact with ER or Golgi membranes where these modifications 
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take place [35, 45]. Ext-Ras shows no evidence of binding to exocytic vesicles but does 
associate with the plasma membrane and become palmitoylated [35]. Interestingly, Ext-Ras 
differed from H-Ras and K-Ras4B, and was not detectable on Arf6-associated endosomes 
(Fig. 7C and C’). Furthermore, Ext-Ras61L did not co-localize with AlexaFluor-transferrin in 
the ERC (Fig. 7D). This was an important control because, although endocytosis via Arf6-
associated vesicles can occur continuously, binding to these endosomes was neither universal 
nor inevitable for a palmitate-modified H-Ras protein.  
The C-terminal domain of H-Ras or K-Ras4B proteins can target GFP to the Arf6 
endocytic pathway  
Because both GDP-bound and GTP-bound forms of H-Ras were found on 
Arf6-associated vesicles, it appeared that the Switch I and Switch II regions of the protein 
(which differ between the GDP vs GTP state) were not likely to be determinants of binding. 
To study the structural requirements for binding to Arf6 endosomes more directly, a GFP 
chimera (GFP-H-tail), having only the last ten C-terminal residues of H-Ras, was tested. 
Identical GFP-H-tail proteins have previously been shown to be correctly modified with 
farnesyl and palmitoyl lipids, and to be targeted to raft-like areas of the plasma membrane 
[21]. As they did with the full-length H-Ras protein, Arf6-Q67L endosomes bound this 
GFP-H-tail protein (Fig. 8A). Arf6-Q67L endosomes also bound a second chimeric version 
of GFP, GFP-K-tail, with the last twenty residues of K-Ras4B (Fig. 8B). This mirrored the 
ability of the full-length K-Ras4B protein to bind Arf6-Q67L endosomes. These results 
indicated that the (farnesylated, fully modified) C-termini of Ras proteins, with either 
palmitates or multiple lysine residues, were sufficient structurally to support binding to 
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Arf6-coated endosomes. Thus, ten Ras C-terminal residues (including lipid modifications) 
were sufficient to direct a protein to Arf6-associated vesicles. 
Discussion 
The studies here provide two notable findings—the absence of H-Ras from 
clathrin-dependent endosomes, and the identity of a second class of vesicles that do bind 
H-Ras. Normal, growth factor stimulated, and oncogenic forms of H-Ras bind 
clathrin-independent endosomes that contain the Arf6 protein. These endosomes are separate 
from, and in addition to, exocytic vesicles of the biosynthetic pathway. Arf6 endosomes 
provide a second, membrane-based mechanism for binding of H-Ras to internal membranes 
that is distinct from the deacylation-controlled cycle between the cell surface, cytosol, and 
internal membranes. Several other clathrin-independent endocytic routes are rapidly being 
defined [16, 25, 46, 47]. It will now be important to learn if H-Ras also utilizes these 
pathways, or only the Arf6-associated endosomes.  
Arf6 endosomes bound both inactive and active forms of H-Ras, and thus provide a 
possible new platform for signaling within the cell. The nucleotide-independence of H-Ras 
endosome binding is consistent with previous reports [11] and with the constitutive nature of 
Arf6-mediated endocytosis [26, 48, 49]. Internal relocation of H-Ras via 
deacylation/re-acylation also operates for both GDP- and GTP-bound forms [8, 9]. 
Interestingly, palmitate turn-over is accelerated when H-Ras is in the GTP-bound form [37], 
suggesting that this form of relocation may be subject to control. Although Arf6 endocytosis 
occurs continuously, it can also be regulated [26, 41, 43]. It remains to be seen how 
stimulation of Arf6-associated endocytosis affects H-Ras-GTP that may bind those 
endosomes. Although the plasma membrane is widely viewed as a static, final destination for 
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Ras proteins, this report adds support to the idea that the amount of Ras at the plasma 
membrane (not just its activation state) may be dynamic and continuously adjustable, by both 
deacylation and endocytosis. 
These studies also confirm the presence of H-Ras in the perinuclear recycling center 
[13] and thus reveal an additional challenge for studies that wish to measure H-Ras signaling 
from internal sites. Because the endocytic recycling center is often embedded within or near 
the Golgi, it may be necessary to distinguish H-Ras on ERC membranes from newly 
synthesized or re-acylated H-Ras on Golgi membranes [9]. 
Properties of Ras proteins that bind to Arf6-associated vesicles 
Our results show that the seven, C-terminal residues of H-Ras, with the 
accompanying farnesyl, methyl, and palmitoyl groups, are sufficient to induce endosome 
binding, just as they also do for association with Golgi membranes [7, 9]. The H-Ras protein 
that is found on Arf6-associated vesicles is likely to be palmitoylated, as it continues to bind 
strongly to membranes. However, palmitoylation cannot be the sole determinant for Arf6-
based endocytosis, because the Ext-Ras protein is palmitoylated on C-terminal cysteines, and 
it failed to enter endosomes. Neither is palmitate a requirement, as non-palmitoylated K-
Ras4B could also bind. 
Because the GFP-H-tail protein resides in low-density (“raft”) membrane 
microdomains [50], its internalization probably takes place from these domains. The 
GFP-K-tail protein and the full-length K-Ras4B-G12V protein, as well as GTP-bound forms 
of H-Ras, which reside outside of the raft-like domains [21] were also observed on 
Arf6-Q67L endosomes. These results are consistent with reports that Arf6-associated 
endosomes can internalize proteins from both types of domains [27]. 
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The role of endosomes in H-Ras signaling 
H-Ras was detected in the vesicle complex that contains insulin receptor, EEA-1 
early endosomes, sorting endosmes, and lysosomes in insulin treated cells [57]. Previous 
study indicated that the cargos that endocytosed though clathrin-independent pathway fused 
vesicles internalized through clathrin-dependent pathway on sorting endosomes where 
further sorting the cargos for recycling back to the plasma membrane or to the late 
endosomes [31]. 
The separation of H-Ras from the clathrin-dependent pathway has special importance 
for interactions of H-Ras with its effector, Raf-1. Both in this work and in studies with 
insulin stimulated- [11] or angiotensin-stimulated [51] cells, activated Raf-1 has been found 
primarily on EEA1-containing endosomes. The presence of Raf-1 on endosomes derived 
from the clathrin-dependent pathway is also consistent with the report that H-Ras-stimulated 
Raf-1 signaling is decreased by a dominant negative dynamin mutant [17]. Combined with 
the H-Ras results of these studies, these reports suggest that at least a portion of 
H-Ras-triggered Raf-1 signals may occur on classical early endosomes, without H-Ras being 
present. This possibility is also consistent with the findings that H-Ras:Raf interactions at the 
plasma membrane are actually quite brief [52].  
In contrast, very little Raf-1 was found on Arf6-associated vesicles that contained the 
activated form, H-Ras61L. Such a limitation in a major Ras effector pathway suggests that 
the spectrum of signals arising from endosomal H-Ras may differ from that of H-Ras on the 
plasma membrane. There is already precedent for selective association of nucleotide 
exchange factors (GEFs), effectors, and GTPase activating proteins (GAPs) with H-Ras that 
is present on Golgi membranes [1, 44, 53]. Furthermore, Arf6-associated endosomes also 
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bind other signaling proteins, such as Src and Rac [27, 41], which could influence or 
contribute to H-Ras signals that might arise from endosomes. 
Ras signaling pathways have previously been linked functionally with Arf6. H-Ras 
stimulates phosphatidylinositol 3-kinase activity, which leads to recruitment and activation of 
the Arf6 nucleotide exchange factor, ARNO [31]. Reciprocally, inhibition of the extracellular 
signal-regulated kinases (ERKs) that are downstream of Ras proteins, specifically impedes 
Arf6-mediated, but not clathrin-mediated, endocytosis [54]. Arf6 and H-Ras collaborate in 
vesicular transport, through co-stimulation of phospholipase D activity needed for vesicle 
budding [55]. Both Arf6 and H-Ras proteins are also central to the pinocytosis and 
membrane ruffling that are caused by growth factors.  
The identification of a specific class of endosomes to which H-Ras can bind connects 
nicely with the previous studies that H-Ras is found on recycling endosomes [13] and 
completes a framework for a new cycle of membrane-bound H-Ras from plasma membrane, 
through internal sites, and back. The studies reported here provide the physical foundation 
that will allow the reciprocal interactions of Arf6 and H-Ras, and the impact of those 
interactions on signaling, to be unraveled.  
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Note Added in Proof 
While this paper was in preparation, Julie G. Donaldson and colleagues reported that 
H-Ras enters cells via Arf6 associated endosomes (Porat-Shliom, N., Y. Kloog, and J.G. 
Donaldson, A Unique Platform for H-Ras Signaling Involving Clathrin-independent 
Endocytosis. Mol Biol Cell, 2007.). 
Figure Legends 
Fig. 1. H-Ras is absent from early endocytic vesicles of the clathrin-dependent pathway. 
All scale bars in this figure = 5 µm. 
(A) Merged images of adherent membrane fragment from sonicated cell expressing 
H-Ras61L. Cell membrane fragments were fixed, incubated with antibodies to H-Ras 
(green, arrow) and clathrin heavy chain (red, arrow head) and fluorescent secondary 
antibodies, and were then examined by indirect immunofluorescence microscopy. 
(B) NIH 3T3 cells stably expressing H-RasWT cDNA were fixed and incubated  
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with antibodies to H-Ras (green, arrows) and EEA1 (red, arrow heads), and detected 
with AlexaFluor-labeled secondary antibodies. Vertical z-stack images of each color 
were deconvolved and merged. 
(C) Merged images of adherent membrane fragment from sonicated cell expressing 
H-Ras61L. Cells were fixed and probed directly with antibodies to H-Ras (green, 
arrow) and EEA1 (red, arrow head), and detected with AlexaFluor-labeled secondary 
antibodies. 
(D) NIH 3T3 cells stably expressing H-RasWT were treated with 10 ng/ml of EGF for 
10 minutes before fixation and incubated with antibodies to H-Ras (green, arrows) 
and EEA1 (red, arrow heads), and detected with AlexaFluor labeled secondary 
antibodies. Vertical z-stack images of each color were deconvolved then merged. 
(E) Merged images of AlexaFluor-transferrin (red, arrowheads) and GFP-H-Ras61L 
 (green, arrows) in a cell transfected and grown for 18 hours, then treated with 
cycloheximide for 6 hours, chilled and exposed to transferrin, then warmed for 1 
minute before fixation. Vertical z-stack images of each color were deconvolved 
before merging. 
(F) Membranes from the post-nuclear supernatant (PNS) in NIH 3T3 cells  stably 
expressing H-Ras-WT or H-Ras 61L were captured with EEA1 antibody (IP). 
Proteins were separated by SDS-PAGE and identified by immunoblotting with 
indicated antibodies. 95% of the sample was loaded in the IP lane, and 5% in the PNS 
lane. 
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Fig. 2. H-Ras is present on endosomes that contain MHC-I and Arf6. All scale bars 
represent 5 µm. 
(A), (A’) and (A”) HeLa cells were transfected with cDNA for GFP-H-Ras61L, 
incubated for 18 hours, and then treated with cycloheximide for 6 hours. During the 
last 30 minutes, anti-MHC-I monoclonal antibody was added to the culture medium. 
Cells were washed for 30 seconds with mild acid to remove surface-bound antibody, 
then were fixed, and stained with mouse secondary antibody (red). Vertical z-stack 
images of each color were deconvolved. The position of several vesicles containing 
both the internalized MHC-I (arrowheads) and GFP-H-Ras61L (arrows) are indicated. 
(A) Fluorescence image showing GFP-HRas61L. (A’) Fluorescence image showing 
MHC-I. (A’’) Merged image of (A) and (A’). 
(B), (B’) and (B”) HeLa cells were transfected with cDNA for Arf6-Q67L-GFP 
(green), incubated for 18 hours then treated with cycloheximide for 6 hours. During 
the last 30 minutes, anti-MHC-I was added to the culture medium. Cells were washed 
briefly with mild acid, fixed, incubated with mouse secondary antibody (red) to detect 
the anti-MHC-I, and imaged. Vertical z-stack images of each color were deconvolved 
and merged. (B) Fluorescence image showing Arf6-Q67L-GFP. (B’) Fluorescence 
image showing MHC-I. (B’’) Merged image of (B) and (B’). 
(C) and (C’) Confocal image of transfected H-RasWT (C, red) on endosomes in cell 
expressing Arf6-WT-GFP (C’, green). Cells were incubated with anti-Ras antibodies 
and AlexaFluor-labeled secondary antibodies, and then examined by indirect 
immunofluorescence microscopy. 
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(D) Enlargement of merged H-Ras (red) and Arf6-WT-GFP (green) images, from 
another cell, to show the beaded appearance (arrow) of Arf6 and H-Ras on the 
endosome membrane. 
(E), (E’) and (E”) Confocal images of a cell transfected with cDNAs encoding 
Arf6-Q67L-GFP (E, green) and activated H-Ras61L (E’, red). (E’’) Merged image of 
(E) and (E’).  
Fig. 3. H-Ras is present on endosomal membranes that contain Arf6. 
(A) Cells were co-transfected with cDNAs encoding GFP-H-Ras61L and 
Arf6-Q67L-HA. Membrane fragments from the post-nuclear supernatant (PNS) were 
captured with anti-HA antibody (IP). Proteins present in the membranes were 
separated by SDS-PAGE and detected on immunoblots with anti-HA (for Arf6-HA) 
and anti-GFP (for GFP-H-Ras). Asterisk (*) shows position of antibody heavy chain 
from the anti-HA antibody used for immunoprecipitation. 
(B) Cells stably expressing H-Ras61L were transfected with cDNA encoding 
Arf6-Q67L-GFP. Membranes from the post-nuclear supernatant (PNS) were captured 
with anti-Ras antibody (IP). Proteins present in the membranes were separated by 
SDS-PAGE and detected on immunoblots with anti-Ras and anti-GFP (for Arf-GFP) 
antibodies. 
(C) Anti-HA antibody isolation performed on membrane fragments from the post-
nuclear supernatant (PNS) of cells stably expressing GFP-H-Ras61L but no 
transfected Arf6 (IP). Proteins present in the sample were separated by SDS-PAGE 
and detected on immunoblots with anti-GFP (for GFP-H-Ras). Asterisk (*) shows 
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position of antibody heavy chain from the anti-HA antibody used for 
immunoprecipitation. 
Fig. 4. EGF exposure results in GFP-RBD recruitment to enlarged endosomes in cells 
expressing H-RasWT and Arf6-Q67L. Confocal images of cells transfected with 
cDNAs encoding Arf6-Q67L-HA (unstained), cellular H-Ras (red), and the 
Ras-binding domain from Raf kinase (GFP-RBD, green) to detect GTP-bound H-Ras. 
At 24 hours after transfection, cells were exposed to EGF for the indicated times, 
fixed, and stained with anti-H-Ras. Arrows indicate H-Ras on plasma membrane or 
on enlarged endosomes that result from expression of Arf6-Q67L; arrowheads 
indicate GFP-RBD on plasma membrane or endosomes; chevrons indicate absence of 
GFP-RBD on membranes. Scale bars = 10 µm. 
(A) and (A’) Control cell that was transfected with all three cDNAs, but not untreated 
with EGF. (A) Fluorescence image showing GFP-RBD. (A’) Fluorescence image 
showing H-RasWT. 
(B) and (B’) Transfected cell treated with 5 ng/ml EGF for 5 minutes. (B) 
Fluorescence image showing GFP-RBD. (B’) Fluorescence image showing 
H-RasWT. 
(C) Merged image of H-Ras-WT and GFP-RBD in transfected cell treated with  
5 ng/ml EGF for 10 minutes. The chevron indicates lack of GFP-RBD on some 
endosomes after 10 minutes exposure to EGF.  
Fig. 5. Very little Raf-1 is present on Arf6 -containing endosomes. All scale bars in this 
figure = 10 µm. 
(A) and (A’) NIH 3T3 cells were transfected with cDNAs for GFP-HRas61L (A, 
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green) and Arf6-Q67L-HA (unstained). Cells were fixed and incubated with anti-Raf-
1 antibody, and AlexaFluor-labeled secondary antibody (A’, red). Vertical z-stack 
images of each color were deconvolved. Arrow indicates an endosome that contains 
GFP-HRas61L and chevron indicates that absence of endogenous Raf-1 on that 
endosome.  
(B) Enlargement of merged box area of (A) and (A’). Arrows indicates endosomes 
that contain GFP-HRas61L but lack of Raf-1. 
(C) Merged images of H-Ras61L (green) and endogenous Raf-1 (red) in NIH 3T3 
cells that were transfected with cDNA of H-Ras61L. Vertical z-stack images of each 
color were deconvolved. Arrow shows both H-Ras61L and Raf-1 are located on the 
plasma membrane. 
(D) Merged images of Arf6-Q67L-GFP (green) and endogenous Raf-1 (red) in cells 
that co-express transfected H-Ras61L and Arf6-Q67L-GFP. 24 hours after 
transfection, cells were fixed, and detected with antibody to Raf-1 and AlexaFluor-
labeled secondary antibody. Vertical z-stack images of each color were deconvolved 
then merged. Arrowhead indicates an endosome with Arf6-Q67L-GFP that lacks 
Raf-1; chevron indicates Raf-1 on a separate structure that lacks Arf6. 
Fig. 6. H-Ras is present in the perinuclear endosomal recycling center. All scale bars in 
this figure = 10 µm. 
(A) and (A’) Confocal images of cell transfected with cDNA for H-Ras61L, treated 
with cycloheximide for 6 hr, exposed to AlexaFluor-transferrin (A, red) for 45 min, 
then fixed and stained with antibody against H-Ras (A’, green). Arrow indicates 
perinuclear accumulation of H-Ras61L; arrowhead indicates transferrin. 
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(B) Merged image of a cell transfected with cDNA for H-Ras61L, treated with 
cycloheximide for 6 hr, fixed, and stained with antibodies for H-Ras (green) and 
giantin (red).  
(C) Boxed area of (B) is enlarged. Arrow indicates H-Ras61L is accumulated on the 
perinuclear region that does not contain giantin (arrow head).  
(D) Cell treated as in (A) and (A’). AlexaFluor-transferrin is shown in red and H-Ras 
is shown in red. 
(E) Boxed area of (D) is enlarged to show separate vesicles of red (transferrin, arrow 
head) and green (H-Ras, arrow). 
Fig. 7. Binding of K-Ras4B and Ext-Ras to endosomes and the endosomal recycling 
center differs from H-Ras. All scale bars in this figure = 10 µm. 
(A) and (A’) Confocal images of cell expressing GFP-K-Ras4B-12V (A, arrow; 
green) and Arf6-Q67L-HA (A’, arrowhead; red) on enlarged endosomes. Cell was 
transfected with cDNAs for GFP-K-Ras4B-12V and Arf6-Q67L-HA, fixed, and 
detected with anti-HA antibody and AlexaFluor-labeled secondary  antibodies. 
(B) Merged confocal images of a cell expressing GFP-K-Ras4B-12V (green) and 
exposed to AlexaFluor-transferrin (red) for 45 minutes, then fixed. Chevron indicates 
perinuclear accumulation of transferrin, but not K-Ras4B in the endosomal recycling 
center. 
(C) and (C’) Confocal images showing Ext-RasWT (C, red) is not present on 
Arf6-WT-GFP (C’, green) enlarged endosomes (arrowheads; green). Chevrons in left 
panel indicate absence of Ext-Ras on Arf6-WT-coated endosomes that can be seen in 
right panel. 
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(D) Merged confocal images of a cell expressing Ext-Ras61L (green) after exposure 
to AlexaFluor-transferrin (red) for 45 minutes. Cell then was fixed and detected with 
antibody to H-Ras and AlexaFluor-labeled secondary antibodies. Chevron indicates 
perinuclear accumulation of transferrin, but not Ext-Ras61L, in the endosomal 
recycling center. 
Fig. 8. C-terminal residues of H-Ras or K-Ras4B proteins can target GFP to Arf6 
endosomes. All scale bars in this figure = 10 µm. 
(A) Merged images of a cell expressing GFP-H-tail (arrow; green) and 
Arf6-Q67L-HA (red). 
(B) Merged images of GFP-K-tail (arrow; green) on Arf6-Q67L-HA (red) 
endosomes. Vertical z-stack images of each color were deconvolved, then merged. 
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CHAPTER 3. BIOLOGICAL ACTIVITY AND SIGNALING OF TWO H-RAS 
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ABSTRACT 
H-Ras protein has been shown to be associated with different microdomains of the 
plasma membrane. However, whether H-Ras activates and signals exclusively from raft or 
non-raft microdomains on the plasma membrane has not been thoroughly elucidated. Here 
two H-Ras variants were used: EHR-Ras, a N-terminal IBV E1 (QI) transmembrane domain 
targeted H-Ras lacking C-terminal cysteine lipidation sites; and Ext-Ras, a palmitoylated 
H-Ras that lacks a farnesyl group but instead has a C-terminal polybasic region. We found 
that EHR-Ras accumulated in non-raft microdomains, whereas Ext-Ras was found 
distributed predominantly in lipid raft containing membranes. Both EHR-Ras61L and 
Ext-Ras61L can activate most of the major Ras downstream signaling cascades including 
MAPK, PI3 kinase-AKT, and JNK pathways, though the extent of activation differs from 
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that of H-Ras61L. Moreover, both EHR-Ras61L and Ext-Ras61L cause differentiation in 
PC12 cells and transformation of NIH 3T3 cells. Thus, our results indicate that H-Ras located 
either in lipid raft and non-raft microdomains can signal and has biological functions, and 
translocation between non-raft and raft microdomains is not a prerequisite for H-Ras 
mediated signaling. 
INTRODUCTION 
The biological composition of the plasma membrane is intricate because it is made of 
lipids that are arranged in distinct microdomains. Broadly, membrane domains can be 
divided into raft and non-raft microdomains based on their biophysical characteristics and 
molecular compositions. Raft microdomains are enriched with cholesterol and sphingolipids. 
They are also highly dynamic and exist in the liquid ordered phase (1–5). In contrast, 
non-rafts are enriched with unsaturated phospholipids and are less ordered than lipid rafts  
(6–8). To date, studies have shown that many proteins distribute themselves either in or out 
of rafts (9, 10). Among these proteins, perhaps the most well known is Ras. Ras is a small 
GTPase that can only signal when it is lipid modified at its C-terminus. This modification 
enables Ras to associate with the inner leaflet of the plasma membrane where the majority of 
Ras mediated signal transduction takes place. Like other GTPases, Ras cycles between its 
activated, GTP bound, and inactivated, GDP conformation. The microdomain localization of 
Ras in the plasma membrane is particularly important because the plasma membrane is the 
major platform from which the Ras signal emanates. While several different isoforms of Ras 
exist, studies using various methods (e.g., biochemical fractionation assays, electron 
microscopy studies, and biophysical methods) have shown that H-Ras is associated with raft 
and non-raft membrane localizations (11–15). However, whether different localizations of 
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H-Ras on the plasma membrane affect signaling initiation and biological functions has not 
been thoroughly elucidated. One popular model suggests that GTP activated H-Ras is 
sequestered on non-raft plasma membranes, while GDP bound H-Ras accumulates in raft 
microdomains (12, 13). This model indicates that although H-Ras associates with both 
plasma membrane microdomains, H-Ras only signals from non-raft domains and must shift 
from lipid rafts to non-rafts in order to activate its downstream signaling cascades. However, 
other studies have suggested that lipid rafts are also associated with Ras signaling (11, 16–
18).  
It has been well established that different lipid modifications of Ras proteins and the 
membrane targeting sequences of Ras can alter its subcellular localization and signaling 
ability. One H-Ras variant, Ext-Ras, is palmitoylated at its C-terminus, but is not 
farnesylated. Furthermore, Ext-Ras contains a polylysine sequence, which helps it to 
associate with the plasma membrane (19). Several studies have shown that the farnesylated 
peptides partition poorly into rafts, suggesting that farnesylated proteins are sequestered in 
non-raft membrane microdomains (20–23). Moreover, many acylated proteins were found to 
interact with membrane rafts (24). Because Ext-Ras lacks farnesyl but is palmitoylated, it 
may be expected that Ext-Ras will be included in raft microdomains. Previous results (19, 
25) showed that the constitutively activated Ext-Ras61L variant has biological functions. Its 
expression resulted in neurite outgrowth in PC12 cells and transformed NIH 3T3 cells (19, 
25). Also, a high level of signal activation was detected in the PI3 kinase pathway in PC12 
cells transfected with Ext-Ras61L. These findings suggest that Ext-Ras61L, unlike 
H-Ras61L, may process signaling activity while associated with lipid rafts. Early reports 
indicated that Ext-Ras is localized both on the plasma membrane and in the cytosol (25), but 
 81
the specific microdomain of the plasma membrane on which it is localized has not been 
determined.  
EHR-Ras is another H-Ras variant. This variant has a transmembrane domain from 
the E1 (QI) protein of the infectious bronchitis virus (IBV) in the N-terminus, followed by a 
H-Ras sequence with the three cysteines mutated to serines in the C-terminus (26). These 
cysteine mutations inhibit lipid modifications of H-Ras, so that this Ras mutant cannot tether 
to the plasma membrane through the C-terminus. The transmembrane domain of EHR-Ras 
has been shown to target H-Ras to the plasma membrane (26, 27). Previous data suggested 
that single-spanning transmembrane peptides with short transmembrane domains tend to be 
excluded from the raft domains, while transmembrane peptides with long transmembrane 
domains are localized to the raft membranes (28, 29). The transmembrane spanning sequence 
of EHR-Ras (27, 30) is relatively short and its length is close to that of other known non-raft 
transmembrane peptides (31). Thus it is possible that EHR-Ras might also be targeted to 
non-raft membranes. Previous results show that the activated form of EHR-Ras, 
EHR-Ras61L, induced neurite outgrowth in PC12 cells and also caused membrane ruffling in 
REF-52 cells. This indicates that EHR-Ras61L can produce biological activity within these 
cells (26). However, the microdomain of the plasma membrane on which EHR-Ras is 
localized has not yet been identified. 
In this study, we investigated whether or not the microdomain localizations impact 
H-Ras signaling initiation and function. We addressed this by using two H-Ras variants, 
Ext-Ras and EHR-Ras. We investigated their microdomain localizations and found that 
Ext-Ras is localized preferentially in the raft microdomains, and EHR-Ras is localized in the 
non-raft microdomains. Compared to other H-Ras chimeras that were designed to tether to 
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lipid rafts on the plasma membrane, Ext-Ras shows typical plasma membrane localizations 
and has a size and membrane anchor position similar to that of H-Ras. Other lipid raft located 
Ras chimeras, such as H-RasC184S and Raichu-tH, showed abundant distributions on the 
endomembranes (17, 32) and lipid raft located Ras chimeras LCK-Ras and Mys-Ha-Ras are 
tethered to the membrane through both their N-terminal and C-terminal membrane anchors 
(18, 33). We found that the two H-Ras variants that we used can signal and induce biological 
activity in NIH 3T3 and PC12 cells. These findings emphasize that both raft and non-raft 
microdomains allow H-Ras signaling and function, and the translocation of H-Ras between 
the lipid raft and non-raft microdomains is not required for generating H-Ras mediated signal 
transduction. In addition, these results demonstrated that both Ext-Ras and EHR-Ras are 
good models for studying raft and non-raft localized Ras. 
MATERIALS AND METHODS 
DNA constructs 
The original DNA constructs of E1 (QI)-22-H-RasWT3S (EHR-RasWT) and E1 
(QI)-22-H-Ras 61L3S (EHR-Ras61L) (34) in pcDNA1 vectors (Invitrogen) were obtained 
from Berthe Willumsen (University of Copenhagen, Denmark). EHR-RasWT was then cut 
out of pcDNA1 and inserted into pcDNA3 using Hind III and EcoR I. EHR-Ras61L was 
made using site directed mutagenesis to mutate the endogenous Gln at position 61 into a Leu. 
The sense oligo used was 5’ CTg gAT ACC gCC ggC CTg gAg gAg TAC AgC gCC 3’ and 
the antisense oligo used was 5’ggC gCT gTA CTC CTC CAg gCC ggC ggT ATC CAg 3’. 
The construction of H-Ras and Ext-Ras DNAs in the pcDNA3 vector has been 
described previously (19). The DNA LYFP-GPI was obtained from the laboratory of A. 
Kenworthy (Vanderbilt University). 
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Cell culture and transfection   
NIH 3T3 cells and 293T cells were cultured in a 37°C incubator in 10% CO2 and 
placed in Dulbecco’s Modified Eagle’s medium supplemented with 10% calf serum plus 
penicillin, streptomycin, glutamine, and sodium pyruvate. The PC12 cells were grown in 
RMPI medium (Gibco) supplemented with 10% heat inactivated horse serum plus 5% fetal 
bovine serum and incubated in 5% CO2. Stable NIH 3T3 cell lines were generated by 
transfection with the appropriate DNA (EHR-Ras61L or EHR-RasWT). G418 disulphate salt 
solution was added after 24 hours at a concentration of 750 µg/ml. The H-Ras61L stable cell 
line expressed the H-Ras61L in the pZIPneo vector. 
NIH 3T3 cells and 293T cells were transfected with Effectene (Qiagen) or SuperFect 
(Qiagen) respectively according to the manufacturer’s recommendations and used after 24 
hours. The transfection of PC12 cells was performed using Lipofectamine (Invitrogen) with 
0.8 µg of DNA per well of a 12-well plate coated with 10 µg/ml laminin in growth medium.   
Antibodies 
The following antibodies were used for immunoblotting: mouse monoclonal anti-Ras 
(BD Bioscience 610010), mouse monoclonal anti-Ras 146-3E4 (Quality Biotech), rabbit 
polyclonal anti-caveolin (Transduction Laboratories C13630), mouse monoclonal 
anti-phospho-ERK (Thr 202/Tyr 204, Cell Signaling 9106), rabbit polyclonal anti-ERK1 
(Santa Cruz Ssc-94), mouse monoclonal anti-phospho-Akt (Ser 473, Cell Signaling 4051), 
rabbit polyclonal anti-AKT (Cell Signaling 9272), mouse monoclonal 
anti-phospho-SAPK/JNK (Thr 183/Tyr 185, Cell Signaling 9255), and rabbit monoclonal 
anti-SAPK/JNK (Cell Signaling 9258). For immunofluorescence, rat monoclonal anti-Ras 
(sc-34) and rabbit polyclonal anti-c-Raf-1 (sc-227) were obtained from Santa Cruz 
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Biotechnology; rabbit polyclonal anti-PI3 kinase p85 (06-195) was obtained from Upstate 
Biotechnology. Goat anti-rat IgG coupled to Alexa Fluor 488, goat anti-rabbit IgG coupled 
with Alexa Fluor 594, and donkey anti-rat IgG coupled with Alexa Fluor 594 were obtained 
from Molecular Probes and were used as secondary antibodies. 
Immunofluorescence 
All cells were plated on coverslips coated with poly-L-lysine (100 µg/ml) and 
fibronectin (500 µg/ml) in PBS. Cells were washed with PBS and then fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. Cells were then permeabilized with 
-20°C methanol and quenched with 50 mM ammonium chloride in phosphate-buffered 
saline. The fixed cells were incubated with a blocking buffer for 30 minutes (2% horse serum 
and 0.4% bovine serum albumin in phosphate-buffered saline, pH 7.4) before undergoing a 
one-hour incubation with a blocking buffer containing the primary antibody. Secondary 
antibodies were also diluted (1:700) in blocking buffer for one hour. The experiments to 
produce adherent plasma membrane fragments were carried out exactly as described 
previously (14). After rinsing, the cover slips were mounted in Vectashield mounting 
medium (Vector Laboratories). 
For photographing adherent membrane fragments, cells were examined using a 60x 
oil immersion Plan Apo lens or a 100x oil immersion Plan Fluor lens with an aperture 
adjustable from 1.3 to 0.6 on a Nikon Eclipse E800 microscope. The images were captured 
by a Spot RT digital camera (Roche Diagnostics) in color or in black and white, imported 
and overlaid in Adobe Photoshop 7.0. Other images were obtained with a Leica DMIRE2 
microscope using a 100x oil immersion PL Fluotar lens with an aperture adjustable from 1.3 
to 0.6 and a Q Imaging Retiga 1300 camera. All the images using the Leica DMIRE2 
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microscope were obtained in black and white, processed in Openlab3.5.1, converted to color, 
and then exported to Adobe Photoshop 7.0 to equalize image intensity prior to merging. For 
some experiments, as indicated in the figure legends, a series of z-stack images were 
acquired using a motorized stage on the Leica DMIRE2 microscope. These images were 
processed using Openlab’s Nearest Neighbor Deconvolution module and exported as above. 
Cell lysis 
NIH 3T3 cells were cultured in 100 mm tissue culture plates. Cells were lysed with 
1.0 ml of lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1% NP-40, and 1 mM 
Na3VO4, 1% protease inhibitor cocktail [Sigma]) on ice for 30 minutes. The lysates were 
then spun at 10,000 x g for 10 minutes, and the supernatant was collected. The 6x 
SDS-PAGE loading buffer (375 mM Tris-HCl, pH 6.8, 6% glycerol, 12% SDS, 15% 
β-mercaptoethanol, 0.15% bromophenol blue) was then added to the collected supernatant. 
Samples were boiled for five minutes, and proteins were separated by SDS-PAGE.  
Subcellular fractionation and density gradient membrane flotation 
Cells were lysed in hypotonic buffer (1 mM Tris, pH 7.4, 1 mM MgCl2 in water) 
containing protease inhibitors and broken up with a 26-gauge needle. The lysates were then 
spun at 1300 x g for 10 minutes at 4°C to remove the nuclei. 5 M NaCl was added to the 
supernatant to a final concentration of 150mM. The supernatant was then spun at 100,000 x g 
for 30 minutes to separate the cytosolic (S100) and membrane fractions. The pellets 
(membrane bound fractions, P100) were resuspended in 0.2% Triton X-100 or 1% Triton 
X-100 on ice for 10 minutes. They were then spun again at 100,000 x g, and the detergent 
soluble (DS) and detergent resistant membrane (DRM) fractions were collected. 
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For a density gradient analysis, the membrane pellet (P100) was resuspended in 
Optiprep™ (60% [w/v] solution of iodixanol in water, density = 1.32g/ml, Sigma D-1556) to 
produce a final concentration of 40% Optiprep™ and then sonicated. Triton X-100 was 
added to sonicated samples at a final concentration of 0.2% or 1% for 30 minutes on ice. The 
samples containing Triton were loaded at the bottom of the centrifuge tube. Decreasing 
concentrations (from 37.5% to 20%) of Optiprep™ buffer, with no Triton, were then added 
carefully to the top of the Triton containing samples. The gradient was then centrifuged at 
4°C for at least 16 hours at 100,000 x g. Samples were collected from each fraction from the 
top of the centrifuge tube, precipitated with trichloroacetic acid, and separated with 
SDS-PAGE. 
Western blots 
Cell lysates, subcellular fractions and OptiprepTM gradient samples were separated by 
SDS-PAGE. Proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Pall 
Life Science) and then incubated in blocking buffer (Vector Labs 10x casein diluted to 1x) in 
TTBS (0.15 M NaCl, 0.05 M Tris-HCl, 0.05% Tween-20, pH 7.4) for 20 minutes at room 
temperature. PVDF membranes were washed in TTBS and incubated with primary antibodies 
overnight at 4°C. The proteins of interest were detected using horseradish 
peroxidase-conjugated goat anti-mouse or goat anti-rabbit secondary antibodies and the 
enhanced chemiluminescence substrates according to the manufacturer’s protocol (Pierce). 
X-ray films of Western blots were scanned with an HP 2300 series scanner/printer and the 
densitometry was quantified by ImageJ software (NIH).  
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Detection of GM1 
OptiprepTM gradient samples were transferred to nitrocellulose membranes and then 
incubated in blocking buffer (Vector Labs 10x casein diluted to 1x) in TTBS (0.15 M NaCl, 
0.05 M Tris-HCl, 0.05% Tween-20, pH 7.4) for 10 minutes at 4°C. Nitrocellulose 
membranes were then washed with TTBS. The gangliosides GM1 were detected with 
horseradish peroxidase-conjugated cholera toxin β subunit (Sigma C-4672, 1:10,000 
dilution) and the enhanced chemiluminescence as described above for Western blot.  
Soft agar assay 
A bottom layer of agar media (1 portion 1.8% agar, 2 portions 2x NIH 3T3 media, see 
“Cell culture”) was plated in a 60 mm tissue culture dish and left to set overnight in the 37 oC 
CO2 incubator to keep the pH from becoming basic. Then NIH 3T3 cells were suspended as 
single cells in normal media (50,000 cells/ml), and 300µl of cells (15,000 cells) were added 
to 1 ml of agar media and carefully added to the base layer. All cell lines used stably 
expressed the desired protein. Colony formation was counted on the 14th day after being 
plated, and any clusters having two or more cells were counted as colony growth. As a 
control, the stable cell lines were also examined by immunofluorescence and stained with 
DAPI, and the percentage of cells expressing Ras proteins was calculated. 
Focus assay 
Cells were transfected with DNA encoding EHR-Ras61L, H-Ras61L, or 
EHR-RasWT. The amounts of DNA were tested at 3 ng and 30 ng/plate for H-Ras61L; 10 
ng, 50 ng, and 100 ng/plate for EHR-Ras61L; 500 ng/plate for EHR-Ras61L. 12–17 days 
after transfection, plates were stained with crystal violet for visualization, and the number 
of foci was quantified. 
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RESULTS  
Description of the different H-Ras variants 
H-Ras accumulates in different membrane microdomains. It was our purpose to 
examine how the locations of H-Ras at different membrane sites of the plasma membrane 
affect signaling and biological functions. To do this, two DNA constructs were used, 
EHR-Ras and Ext-Ras; these were expected to tether to different microdomains of the 
membrane, non-rafts and rafts. Both the EHR-Ras and Ext-Ras maintain the effector binding 
regions of the H-Ras and preserve the GTP-binding properties of Ras (19, 26). 
The logic in designing the EHR-Ras protein is as follows: For the EHR-Ras protein, a 
3S (SMSSKSVLS in the C-terminus) mutated H-Ras (FIG. 1) was fused with the N-terminal 
E1 (QI, Gln37→Ile) mutated transmembrane target signal of the infectious bronchitis virus 
(IBV)(30). The C-terminus of the 3S H-Ras does not associate with the plasma membrane 
(PM) because the 3S mutation eliminates H-Ras lipidation. However, the N-terminal E1 (QI) 
domain has been shown to effectively target proteins to the plasma membrane (26, 27, 30). In 
addition, the transmembrane portion of EHR-Ras will cause the protein to transit the Golgi 
and undergo exocytic transport to the plasma membrane (26). The 3S-mutated Ras portion of 
EHR-Ras is always located in the cytosol (FIG. 1). Between the N-terminal transmembrane 
domain and the 3S-mutated H-Ras is a 22 amino acid linker region (FIG. 1). This linker 
region functions as a spacer between the membrane targeting domain and the conserved 
domain (26, 27). The single transmembrane spanning sequence of the E1 (QI) domain is 
short, and we hypothesized that this sequence will cause this chimeric protein to localize to 
the non-raft microdomain of the plasma membrane (28, 29, 35).  
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We used the H-Ras variant Ext-Ras as a version of H-Ras that might be targeted to 
rafts. Compared to the normal H-Ras, the ‘X’ residue of CAAX motif in Ext-Ras was 
replaced with six lysine residues. To ensure association with membranes, six lysine residues 
were engineered in Ext-Ras to produce an ionic interaction with the plasma membrane (FIG. 
1). Thus, Ext-Ras is not farnesylated, but can be palmitoylated due to the maintenance of the 
cysteine residues in the C-terminus (19). Ext-Ras was found to be distributed widely on the 
plasma membrane and, importantly, was absent from internal membranes (19, 25). Since 
palmitoylated proteins prefer to partition into raft domains (23), we expected that Ext-Ras 
would tether to the lipid raft regions of the plasma membrane. To ensure association with 
membranes, six lysine residues were engineered in Ext-Ras to produce an ionic interaction 
with the plasma membrane (FIG. 1). 
Expression of EHR-Ras and Ext-Ras in NIH 3T3 cells 
In order to check whether EHR-Ras and Ext-Ras were targeted as anticipated to either 
raft or non-raft microdomains, we first determined whether these proteins were expressed in 
the cells and localized to the plasma membrane. The DNAs of the EHR-Ras and Ext-Ras 
constructs were transfected into the NIH 3T3 cells, and the distributions of these Ras variants 
within the cells were detected by immunofluorescence with an anti-H-Ras antibody. 
EHR-RasWT was shown to be present on the plasma membrane (FIG. 2A). We also found 
some Ras staining on the ER and Golgi in addition to the plasma membrane staining in some 
other cells, as expected from the presence of a transmembrane domain that can direct 
transport through the conventional exocytic pathway (data not shown). EHR-Ras61L, the 
constitutively active form of EHR-Ras, is localized in the NIH 3T3 cells in a similar fashion 
as EHR-RasWT (data not shown). In order to monitor the locations of EHR-Ras on the native 
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plasma membranes, we adopted a technique in which the top layer of the cells was removed 
by sonication without any detergent or solvent treatment. Cells were grown on coverslips and 
then removed by sonication, leaving behind membrane fragments adhered to the coverslips. 
The localizations of Ras on the remaining single layer PM were detected by 
immunofluorescence. Using this technique, EHR-Ras61L localization on the native PM 
could be clearly seen (FIG. 2B). 
Ext-Ras protein was localized to the PM, producing an outline of the cells as shown 
by the immunofluorescent image in FIG. 2C. A noticeable portion of Ext-Ras remained 
cytosolic as anticipated (19). We also found that the cellular localization of the GTP bound 
Ext-Ras, Ext-Ras61L, was similar to that of Ext-RasWT (data not shown). Localization of 
Ext-Ras on the PM was clearly observed in adherent membrane fragments (FIG. 2D). Plasma 
membrane association was also confirmed in 293T cells transfected with the EHR-Ras and 
Ext-Ras DNAs, with staining patterns identical to those observed for NIH 3T3 cells (data not 
shown). Overall, these results demonstrated that we have successfully expressed EHR-Ras 
and Ext-Ras in NIH 3T3 cells, and a substantial amount of each protein is localized to the 
plasma membrane.  
EHR-Ras associates with detergent sensitive membrane fractions whereas Ext-Ras 
preferentially associates with detergent resistant membrane fractions 
One characteristic of lipid rafts is that they are not fully solubilized by non-ionic 
detergents such as Triton X-100 at low temperatures; therefore, they are also called detergent 
resistant domains or DRMs. As one way to determine whether EHR-Ras or Ext-Ras was 
localized to lipid raft microdomains, we tested whether they were present in DRM or 
non-DRM membrane fractions. For this assay, cellular membranes (P100) from NIH 3T3 
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cells that stably expressed EHR-Ras61L or GFP-H-Ras 61L (positive control) were separated 
from the cytosol (S) by centrifugation and then exposed to different concentrations of cold 
Triton X-100 detergent to assess detergent resistance (lipid raft association). The membrane 
bound fraction (P100) was treated with 0.2% Triton X-100 on ice for 10 minutes to solubilize 
non-raft membranes, and then another high-speed spin was performed to separate insoluble 
components (raft domains) from the solubilized material. The detergent soluble membrane 
fractions (DS) and detergent resistant membrane fractions (DRM) were collected, and the 
Ras protein content in each fraction was examined by immunoblotting. Western blots of 
these fractions (FIG. 3A) clearly indicated that almost all EHR-Ras61L was associated with 
the detergent soluble membrane fractions (DS), and so was the non-raft localized GFP-H-Ras 
61L, as anticipated. As expected, this fraction also contained a non-raft associated protein 
marker, the transferrin receptor. In contrast, the detergent resistant membrane fractions 
(DRM) contained most of the caveolin-1, a known protein marker for DRMs (FIG. 3A). The 
results showing the presence of GFP-H-Ras61L on the detergent soluble membrane fractions 
are in agreement with the current understanding of H-Ras61L localization on the non-raft 
membranes (12). The EHR-Ras61L protein was observed as multiple bands in the Western 
blot due to its multiple glycosylation states in the E1 (QI) extracellular region. A similar 
experiment with NIH 3T3 cells expressing EHR-RasWT showed that this protein was also 
entirely extracted into the detergent soluble fraction by treating the membranes with 0.2% 
Triton X-100 (data not shown).  
To determine the membrane fractions that contain Ext-Ras, similar experiments were 
conducted in NIH 3T3 cells that were transfected with Ext-Ras61L. Cell lysates were 
prepared under the treatment of 0.2% ice cold Triton X-100 for 10 minutes, and then 
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centrifuged to separate the cytosolic/detergent soluble fraction from the pellets (0.2% Triton 
X-100 resistant fraction). The Western blot of these fractions showed that a considerable 
amount of Ext-Ras existed in the 0.2% Triton resistant fraction, although a portion of 
Ext-Ras was also present on the cytosolic/detergent soluble fraction as expected (data not 
shown) (19). In order to test whether the membrane domains that Ext-Ras associated with are 
resistant to a higher concentration of detergent and whether this is characteristic of other cell 
types, we conducted similar experiments in Cos-1 cells that were transfected with 
Ext-Ras61L or H-Ras61L (positive control) DNA. Cell lysates were centrifuged to separate 
the cytosolic fraction (S) from the membrane bound fraction. This membrane bound fraction 
(P100) was then treated with 1% Triton X-100 on ice for 10 minutes to solubilize non-DRM 
membranes (DS) and separate them from those that were detergent resistant (DRM). Another 
high-speed centrifugation was performed, and the DS and DRM fractions were collected. A 
Western blot of the samples clearly indicated that H-Ras61L had been completely dissolved 
in the 1% Triton X-100 (DS), whereas a portion of the Ext-Ras61L remained associated with 
the detergent resistant fractions (DRM, FIG. 4B). A considerable amount of Ext-Ras and 
H-Ras proteins was found in cytosolic fractions (S). This probably represents immature 
Ext-Ras and H-Ras proteins that lack lipid modifications and thus are not associated with the 
plasma membrane (19).  
EHR-Ras associates with non-raft membrane fractions whereas Ext-Ras associates with 
raft membrane fractions in density gradients 
As an additional test to determine how EHR-Ras and Ext-Ras proteins partition in 
membranes, density gradient with ultracentrifugation was used to isolate membrane fractions 
based on the buoyancy and detergent insolubility. Previously prepared membrane samples 
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(P100) were exposed to an ice-cold Triton X-100 extraction protocol before the gradient 
separation. The gradient ranged from 20–37.5% Optiprep™ with five intermediate 
progressions to allow for a well-defined separation between raft and non-raft associated 
proteins due to their buoyancy (raft) or lack thereof (non-raft). The markers caveolin-1 and 
ganglioside GM1 were used to monitor the localization of DRMs in the gradients.  
In the gradients where membranes were pretreated with 0.2% Triton X-100, both 
caveolin and GM1, which remain in lipid raft containing fractions, were found in the least 
dense regions of the gradient (FIG. 4A). More than 70% of H-Ras61L was identified in the 
bottom fractions. About 80% EHR-RasWT was also identified in the more dense, non-raft 
fractions (FIG. 4A). When a similar experiment was preformed in NIH 3T3 cells, 
EHR-Ras61L again was associated with non-raft fractions (data not shown). However, about 
60% of Ext-Ras61L was detected in the more buoyant, lipid raft containing fractions (FIG. 
4A).  
For the gradients where membranes were pretreated with a higher concentration of 
detergent, 1% Triton X-100, about 90% of H-Ras61L was observed in the densest fractions, 
whereas 30% of Ext-Ras61L still migrated to the lighter, buoyant membrane fractions (FIG. 
4B). The 1% Triton X-100 also extracted some of the caveolin to more dense fractions. 
Taken together, these subcellular fractionation assays and density gradient 
experiments showed that the distribution of EHR-Ras and Ext-Ras at the cell membranes 
differ noticeably. EHR-Ras is distributed in the non-DRM, whereas Ext-Ras is distributed on 
the membrane fractions that are less sensitive to the detergent treatment (DRM), which likely 
represents the lipid rafts.  
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Ext-Ras binds tightly to detergent resistant microdomains, while EHR-Ras is easily 
extracted upon detergent treatment in native plasma membranes 
From the previous subcellular fractionation assays of cell homogenates, we found that 
EHR-Ras was distributed on the detergent soluble membrane fractions (non-DRM), while the 
majority of the Ext-Ras was found in detergent resistant fractions (DRM). To determine how 
strongly these Ras variants bind to these microdomains in native cellular membranes, we 
examined their sensitivity to detergent extraction in the plasma membranes of intact cells. 
NIH 3T3 cells co-expressing a glycosylphosphatidylinositol anchored YFP protein 
(LYFP-GPI), a lipid raft maker, along with EHR-Ras61L or EHR-RasWT, were treated with 
Triton X-100 before fixation and immunofluorescence. Treatment of membranes with ice 
cold 0.2% Triton X-100 does not dissociate the lipid rafts but solubilizes the rest of the 
membranes (non-rafts). Both EHR-Ras61L and EHR-RasWT were almost entirely dislodged 
from the membranes treated with 0.2% Triton X-100, while LYFP-GPI, a marker indicating 
the lipid raft regions of the cell, was retained (FIG. 5A). Similar results were obtained when 
293T cells expressing EHR-Ras and LYFP-GPI were treated with either 0.2% or 1% Triton 
X-100 (data not shown). EHR-Ras proteins were completely extracted while LYFP-GPI was 
retained.  
To test how strongly Ext-Ras binds to lipid rafts, NIH 3T3 cells were transfected with 
the Ext-Ras61L construct and cultured on coverslips. When the cells were treated with ice 
cold 0.2% Triton X-100 as described above for EHR-Ras61L, most of the cell body remained 
intact (data not shown). In order to see more clearly how strongly Ext-Ras binds to lipid rafts, 
in the following experiment on native plasma membranes, the cell body was removed by 
sonication, leaving adherent membrane fragments that were directly treated with ice cold 
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0.2% Triton X-100 or control buffer for five minutes and then fixed. The membrane 
fragments were labeled with antibodies to H-Ras and examined by immunofluorescence. 
This enabled us to detect the Ras proteins on the single layer of the plasma membrane in situ. 
After treatment of the sonicated membranes with 0.2% Triton X-100, much of the 
Ext-Ras61L remained undissolved (FIG. 5B). Even after treatment with a higher 
concentration (1%) of TX-100, Ext-Ras61L remained associated with the membrane 
fragments (FIG. 5B). Similar results were also found for NIH 3T3 cells expressing 
Ext-RasWT that were treated with 1% TX-100 (data not shown). In the control experiments 
for NIH 3T3 cells transfected with H-Ras61L (FIG. 5B), the H-Ras61L protein was partially 
extracted when membrane fragments were treated with 0.2% TX-100 and was completely 
dislodged under the treatment of 1% TX-100. 
These experiments demonstrated that both the activated and inactivated forms of 
Ext-Ras associate tightly to the detergent resistant microdomain of the plasma membrane, 
whereas EHR-Ras localizes to a plasma membrane microdomain that is sensitive to the 
detergent. These results also support the idea that EHR-Ras is localized to non-raft 
microdomains, whereas Ext-Ras preferentially accumulates in lipid rafts of the native cellular 
membrane. 
Ext-Ras is not co-localized with caveolin-1 
Caveolae, a specialized type of lipid rafts, are small invaginations of the PM that are 
characterized by the presence of the protein caveolin-1 (36). Reports showed that H-Ras61L, 
which was localized to the non-DRM fractions of density gradients, was poorly co-aligned 
with caveolin-1 on adherent plasma membrane fragments (14). The previous experiments 
suggested that Ext-Ras is distributed on the DRMs. It would be of additional interest to know 
 96
on which subset of detergent resistant microdomains, caveolae or non-caveolae, Ext-Ras 
resides.  
In order to document the native microdomain localizations of Ext-Ras clearly, we 
also used the sonication technique described above. Antibody staining of endogenous 
caveolin-1 and Ext-Ras61L showed numerous small dots on the membrane fragments, but 
there was no overlap between the Ext-Ras61L and caveolin-1 (FIG. 6 column 4), except on 
the edges of the membrane patch (FIG. 6 column 3). This overlap on the edges is attributed 
to a fold-back of the membrane fragment. In similar experiments with NIH 3T3 cells 
transfected with Ext-RasWT, Ext-Ras also did not co-align with the caveolin-1 on the plasma 
membrane fragments (data not shown). These results show that Ext-Ras is located on the 
non-caveolae microdomains of lipid rafts on the plasma membrane, which is the same as that 
for H-RasWT (14). 
EHR-Ras61L recruits Raf-1 to the plasma membrane while Ext-Ras61L is less efficient 
It has been previously demonstrated that oncogenic H-Ras has the ability to engage 
Ras effectors on the plasma membrane. We were interested in determining whether the 
EHR-Ras or Ext-Ras variants recruit Ras effectors to the plasma membrane, and if so, 
whether they recruit the same effectors that H-Ras recruits. 
As a first approach to determine whether EHR-Ras61L and Ext-Ras61L recruit the 
downstream effector, Raf-1, to the plasma membrane from their different submembrane 
localizations, we utilized whole cell immunofluorescence to study the cells that were 
transfected with these Ras constructs.  
In the cells expressing EHR-Ras61L proteins, both EHR-Ras61L and Raf-1 were 
evident on the plasma membrane (FIG. 7A, column 1). Raf-1 was also located on the 
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ER/Golgi membranes as well, where EHR-Ras was present. This result indicates that 
activated EHR-Ras has the ability to recruit Raf-1 on cellular membranes. In the 
untransfected cells, however, Raf-1 was not recruited to the plasma membrane or 
endomembrane, as expected (data not shown).  
However, in a similar double-labeled immunofluorescence experiment with cells 
expressing Ext-Ras61L, little association of Raf-1 with the PM was seen (data not shown). 
There was particular difficulty in detecting Raf-1 at the plasma membrane in cells expressing 
Ext-Ras61L due to the significant amount of Ext-Ras61L that was present in the cytosol that 
could also bind Raf-1.  
To visualize Ext-Ras61L and effectors that it might recruit to the plasma membrane 
more clearly, we attempted to utilize the adherent membrane fragment technique to monitor 
effector recruitment and determine whether the effectors Raf-1 and PI3-kinase co-localize 
with Ras proteins on native (without detergent treatment) plasma membranes. We first 
conducted a control experiment with H-Ras to test the validity of this technique for the study 
of effector recruitments. NIH 3T3 cells were transfected with H-RasWT and GFP-RBD (GFP 
tagged Ras-binding domain of Raf-1) and serum starved overnight before some of the cells 
were treated with EGF. Both the treated and non-treated cells were sonicated, washed, and 
fixed. The adherent cell membranes were stained with anti-Ras antibody. FIG. 7B (0 min) 
shows that before EGF treatment, though H-Ras was easily observed on the plasma 
membrane, little GFP-RBD was present. However, after the cells were treated with 10ng/ml 
EGF, GFP-RBD was clearly seen on the PM. These experiments recapitulate the current 
opinion (37, 38) that activated Ras (GTP bound) can recruit Raf via RBD to the plasma 
membrane. The ability of the sonicated membranes to retain Ras in a GTP-bound form that 
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was capable of associating with a Ras-binding domain of an effector led us to further utilize 
this technique in testing the recruitment of the full-length, endogenous effectors by Ras 
variants on the plasma membrane. 
We therefore applied the adherent membrane fragment technique to the cells 
expressing Ext-Ras61L, H-Ras61L or H-RasWT respectively. As observed from the 
immunofluorescence of the cells, although the staining of the Ext-Ras61L was very intense, 
on adherent membrane fragments from cells expressing Ext-Ras61L, little Raf-1 was 
observed (FIG. 7A, column 2). In parallel, cells expressing H-Ras61L (FIG. 7A, columns 3) 
and H-RasWT (FIG. 7A, columns 4) were probed for recruitment of Raf-1 to the plasma 
membrane. On adherent membrane fragments, numerous green fluorescent patches were 
visible, marking the presence of H-RasWT or H-Ras61L. Punctuated staining of endogenous 
Raf-1 (red) on the PM was clearly seen in the cells that expressed the constitutively GTP 
bound H-Ras61L, and many of these dots co-localized with that of H-Ras61L. In contrast, 
few areas of Raf-1 staining were observed for membrane fragments from cells that expressed 
H-RasWT. This indicated that the translocation of Raf-1 to the PM is increased when H-Ras 
is activated. The staining for the endogenous Raf-1 in the cells expressing Ext-Ras61L gave a 
very different result from that of H-Ras61L; Raf-1 was poorly translocated to the plasma 
membrane in cells that expressed GTP bound Ext-Ras. Overall, these observations show that 
Raf-1 engages with activated EHR-Ras, which resides in non-raft microdomains of the 
plasma membrane, but does not engage as well with activated Ext-Ras that is accumulated on 
the lipid rafts. 
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Both EHR-Ras61L and Ext-Ras61L showed co-localization with p85 on the PM  
We then examined the recruitment of another H-Ras effector, PI3 kinase. GTP-bound 
H-Ras can bind to the p110 α-catalytic subunit of PI3 kinase. We were interested to know 
whether the differentially targeted EHR-Ras61L and Ext-Ras61L proteins recruit PI3 kinase 
in similar or different manners. To determine how much PI3 kinase is present on the native 
PM and whether it co-localizes with these Ras variants, we again used the adherent 
membrane fragment technique. Antibody to the p85 regulatory subunit of PI3-kinase was 
used to detect the location of the PI3-kinase. In the NIH 3T3 cells expressing EHR-Ras61L, 
the non-raft localized Ras variant, a little p85 was present on the PM (FIG. 8A, column 1). 
For plasma membranes of cells expressing Ext-Ras61L, some p85 was present on the PM 
(FIG. 8A column 2). As a control experiment, membrane fragments from cells expressing 
H-Ras61L were also probed for the presence of p85 (FIG. 8A, column 3). Both H-Ras61L 
and p85 were present on the PM with many sites of co-localization observed.  
In order to quantify the degree of co-localization between p85 and Ras variants such 
as EHR-Ras61L, Ext-Ras61L, and H-Ras61L, single layers of the plasma membranes that 
adhered to the coverslips were examined. The center of each membrane fragment was studied 
in order to exclude rolled or doubled over membranes. Digital thresholding was applied 
manually to the fluorescent images that revealed the p85 and H-Ras proteins of the cells. 
The images were further analyzed by integrated morphometry analysis (IMA) using 
MetaMorphTM 7.1.3 software (Molecular Devices, Downington, PA). Briefly, these methods 
enable the regions of interest to be isolated into closed regions based on the gray levels of 
each pixel, and false positives are then filtered out by the chosen threshold parameters  
(39–41). After that, the co-alignment of the pixels between each pair (p85 and H-Ras) of the 
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images was quantified by the "Measure Colocalization" subroutine in MetamorphTM. A 
control experiment was also set up to test the threshold adjustment efficiency. Caveolin-1 on 
membrane fragments was labeled using both rabbit and mouse primary antibodies and 
detected with rabbit-specific and mouse-specific secondary antibody fluorescence probes 
(green and red). We adjusted the threshold in these control images so that the fluorescent 
signals that showed good intensity and relatively clear borders were selected and used while 
the background noise was filtered out. The co-alignment of the paired thresholded images 
that represented the green and red fluorescent signals from caveolin-1 was quantified. A 95% 
co-alignment was observed (data not shown). This number is very close to the 100% 
theoretical co-alignment and thus ensures that the threshold was adjusted effectively. The 
threshold was adjusted in a similar manner when measuring the co-alignment of the images 
produced from different Ras variants with staining that represented p85 and H-Ras proteins. 
Co-alignment for p85 and EHR-Ras61L was about 7%; for p85 and Ext-Ras61L 
co-alignment was about 15%; for p85 and H-Ras61L co-alignmentwas about 25%. These 
data suggest that, although Ext-Ras61L and EHR-Ras61L recruit the p85-PI3 kinase effector 
to the plasma membrane, the amount of co-localization was lower for the H-Ras61L. 
Biochemical signaling of EHR-Ras61L and Ext-Ras61L  
Because EHR-Ras61L and Ext-Ras61L co-localize with and recruit Raf-1 and 
p85-PI3 kinase to the plasma membrane, we wanted to know whether these two Ras variants 
also trigger events downstream of these effectors in their associated signaling pathways. 
Raf-1 signals via the MAPK pathway, and its activity results in the activation of ERK1/2 
observed by phosphorylation. Activation of PI3 kinase leads to phosphatidylinositol 
(3,4,5)-trisphosphate (PtdIns [3,4,5] P3) production, which results in phosphorylation and 
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activation of AKT(42). In the JNK pathway, the activation of Ras can lead to the 
phosphorylation of c-Jun NH2 terminal kinases (JNK1 and JNK2) through the 
Ras-MEKK-JNK pathway (43). 
To address the question of pathway activation, we utilized NIH 3T3 cells that stably 
expressed either EHR-Ras61L or Ext-Ras61L DNA and detected the activation of Ras 
downstream pathways by immunoblotting of cell lysates. Experimental results were 
compared to those of the control cells stably transfected with H-Ras61L. The relative 
expression level of each target protein was determined by Western blots with the anti-H-Ras 
antibody. We found that Ext-Ras61L had an expression level similar to that of H-Ras61L, 
while the EHR-Ras expression level was three to four times higher than that of H-Ras61L 
(FIG. 9A). EHR-Ras showed multiple bands due to its multiple glycosylation states. 
We then examined whether EHR-Ras61L or Ext-Ras61L activates the ERK pathway 
using Western blots to detect ERK1/2 phosphorylation. As shown in FIG. 9B, cells 
expressing the constitutively activated EHR-Ras61L showed a high level of phosphorylated 
ERK1/2, but less than that of the control, H-Ras61L expressing cells. A low ERK1/2 
activation was found in the stably transfected Ext-Ras61L cell line. This finding is in 
agreement with our previous work that showed low activation of the Raf/MEK/ERK pathway 
by Ext-Ras61L in PC12 cells (19). 
In examining AKT pathway activation, results in FIG. 9C demonstrated that cells 
expressing Ext-Ras61L effectively activated AKT, and cells expressing EHR-Ras61L 
showed a weak AKT activation. For the control, a two-fold higher level of AKT activation 
was achieved in cells stably expressing H-Ras61L in comparison to cells expressing 
Ext-Ras61L.  
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The JNK pathway can also be activated by H-Ras in NIH 3T3 cells, although JNK 
phosphorylation can occur independently of Ras (44, 45). For Ext-Ras61L and EHR-Ras61L 
expressing cell lines, a considerable level of JNK activation was observed, with higher 
phosphorylation in Ext-Ras61L compared with EHR-Ras61L cell lines (FIG. 9D). 
Furthermore, activation of JNK in Ext-Ras61L cells was similar to that found for H-Ras61L 
cells. Though the signal intensities generated by these H-Ras variants, pERK, pAKT, and 
pJNK, were noticeably different, these findings do in fact demonstrate that both 
EHR-Ras61L and Ext-Ras61L variants, in their corresponding non-raft or raft microdomains, 
produce signals. 
Biological activity of EHR-Ras61L and Ext-Ras61L as seen in PC12 cells 
We examined whether the EHR-Ras61L and Ext-Ras61L variants that have the 
ability to activate downstream signaling pathways initiate a biological response. Activated 
H-Ras is known to cause several changes in PC12 cells including cessation of cell growth, 
rearrangement of the actin cytoskeleton, and cell differentiation as evidenced by neurite 
extension (46), whereas the non-activated H-Ras does not initiate these changes. We 
therefore tested the biological activity of EHR-Ras61L and Ext-Ras61L protein variants in 
PC12 cells by examining the morphology of the cells. For comparison, PC12 cells were 
stimulated with nerve growth factor (NGF) or transfected with H-Ras61L. Neurite-like 
extensions of the cell body were observed upon transfection with H-Ras61L. These were 
similar in shape and size to those caused by treatment with NGF (FIG. 10).  
After transfecting cells with EHR-Ras61L, membrane extensions could be clearly 
seen within 72 hours (FIG. 10). These neurite extensions were different from those resulting 
from NGF treatment or transfection with H-Ras61L. EHR-Ras61L produced multiple neurite 
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outgrowths, and the cell bodies were very flattened. For cells transfected with Ext-Ras61L, a 
very different phenotype from H-Ras61L was observed. The cell bodies were broader, and 
the edges were ruffled with large lamellipodia. Cells that expressed Ext-Ras61L often 
generated 4–5 neurite extensions per cell (19). In addition, the neurites showed dramatically 
more kinks. Moreover, the time for generating extensions was shorter than that of cells 
expressing H-Ras61L (19). Despite the distinct difference in appearance of the neurite 
extensions, these findings show that EHR-Ras61L and Ext-Ras61L, which localized 
preferentially to non-raft or raft membrane microdomains, can induce extensions of neurites 
in PC12 cells.  
Loss of anchorage-dependant growth in EHR-Ras61L transfected cells 
Anchorage-independent growth is a hallmark of transformed cells, as compared to 
normal cultured cells, which must adhere to the bottom of the culture dish in order to grow. 
To determine if EHR-Ras61L expression triggers anchorage-independent growth, NIH 3T3 
cells stably expressing EHR-Ras61L were plated in soft agar and cell colony growth was 
compared to cell colony growth on plates of cells transfected with GFP-H-Ras61L or 
EHR-RasWT. Results for similar experiments using Ext-Ras61L and Ext-RasWT have been 
published (19). 
Cells transfected with EHR-Ras61L or GFP-H-Ras61L. Colonies that were clusters 
with two or more cells were counted as growth. The cells that expressed EHR-Ras61L and 
GFP-H-Ras61L showed 22% and 47.3% colony growth in the soft agar, respectively (FIG. 
11D). The colonies formed by EHR-Ras61L were smaller and slower growing than those 
formed by H-Ras61L. In comparison, Ext-Ras61L-transformed cells readily formed colonies 
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in soft agar, similar to H-Ras61L expressing cells (19). For the control, EHR-RasWT 
expressing cells showed almost no growth in soft agar (see FIG. 11A and D).  
Another assay for anchorage-independent growth is the focus assay. Transformed 
cells continue to grow, even under confluent conditions, by growing on top of each other in a 
pile called a focus. Untransformed cells are growth inhibited upon contact with neighboring 
cells. Thus, it is possible to quantify the level of transformation by determining the number 
of foci. After transfection of RAT1 cells with H-Ras61L, EHR-Ras61L, or EHR-RasWT, the 
cells were allowed to grow and foci were quantified twelve to seventeen days later. The 
plates of cells that expressed EHR-Ras61L formed a significant number of foci but less than 
that observed on plates of cells expressing H-Ras61L (Table 1). In contrast, no foci were 
produced after transfection with EHR-RasWT. The procedure was also performed in NIH 
3T3 cells, and transformation was similarly confirmed (data not shown). Ext-Ras61L DNA 
also effectively transformed cells and caused robust focus formation. The transformation 
activity of the cells expressing Ext-Ras61L was comparable to that of the cells expressing 
H-Ras61L. Ext-RasWT produced almost no focus formation in NIH 3T3 cells (19).  
Overall, these experiments clearly showed that both EHR-Ras61L and Ext-Ras61L, 
which reside in different membrane microdomains (raft or non-raft), prompted 
transformation. Thus, the non-raft localized EHR-Ras61L and raft localized Ext-Ras61L 
maintain aberrant growth characteristics of an oncogenic Ras protein in NIH 3T3 cells.  
DISCUSSION 
To date, many reports have indicated that H-Ras is associated with both raft and 
non-raft microdomains of the plasma membrane (47). As we gain more knowledge 
concerning the role membrane microdomain locations play in H-Ras signaling initiation and 
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biological functions, we will also better understand both the mechanism and the function of 
Ras signal transduction within the cell and the nature of the plasma membrane.   
To study whether or not the microdomain localizations impact H-Ras signaling 
initiation and function, we used two H-Ras variants, EHR-Ras and Ext-Ras, designed to 
target different microdomains of the plasma membrane, non-raft and raft. We used several 
methods to study the microdomain targeting specificity of EHR-Ras and Ext-Ras: membrane 
fractionation, density gradient separation, and adherent native membrane 
immunofluorescence. Our results demonstrated that EHR-Ras is localized to the non-raft 
microdomains of the plasma membrane, and Ext-Ras is localized preferentially to the raft 
regions of the plasma membrane. Other reported H-Ras chimeras have been designed to 
tether to lipid rafts on the plasma membrane (17, 18, 32, 33). H-RasC184S, Raichu-tH, 
Mys-Ha-Ras, and LCK-Ras were all found to be associated with lipid rafts. In H-RasC184S, 
one palmitoylatable residue in the C-terminus of H-Ras, 184 cysteine, was mutated to serine 
(32). Raichu-tH contains an YFP, an H-Ras conserved region, a Ras-binding domain of Raf 
(RBD), and a CFP in its N-terminus. In the C-terminus, Raich-tH keeps the membrane 
anchor of H-Ras, which consists of the last nine amino acids. In Mys-Ha-Ras, the residues 
that enable myristoylation were linked to the N-terminal of H-Ras to generate this chimera. 
The residues that enable palmitoylation, myristoylation, and membrane targeting in LCK 
were fused to the N-terminus of a palmitoylation deficient H-Ras variant, H-Ras181, 184S, to 
generate the LCK-Ras. We showed that Ext-Ras is localized exclusively on the plasma 
membrane, whereas H-RasC184S and Raichu-tH chimera showed abundant distributions on 
the endomembranes (17, 32). Our results also demonstrated that, similarly to H-Ras, Ext-Ras 
also tethers to the plasma membrane via its C-terminus. In contrast, the Mys-Ha-Ras chimera 
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is tethered to the membrane through its N-terminal myristoylated residues in addition to the 
C-terminal lipid anchor sequence from H-Ras (33); the LCK-Ras chimera is tethered to the 
membrane both through its N-terminal lipid modification and C-terminal farnesylation motif 
(18). Moreover, since the Raichu-tH chimera also contains several additional tagged protein 
sequences, the size of this chimera protein is much larger than that of H-Ras (17). On the 
other hand, Ext-Ras has a molecular weight similar to that of H-Ras.  
E1 (QI) transmembrane sequence targets Ras to the non-raft domains whereas the 
C-terminal membrane anchor in Ext-Ras targets Ras to the lipid rafts 
Previously, the Donoghue group constructed EHR-Ras proteins to test whether these 
fusion Ras proteins had cell transformation ability in the absence of C-terminal lipid 
modifications and whether EHR-Ras could be targeted to the plasma membrane (27). 
However, which microdomain EHR-Ras resides in was not determined. Our results confirm 
that EHR-Ras is located on the plasma membrane. Moreover, we found that EHR-RasWT 
and EHR-Ras61L are present on the non-raft domains of the plasma membrane, which not 
only indicates the microdomain locations of EHR-Ras, but also shows the activation state of 
Ras does not affect EHR-Ras microdomain localization. The fact that EHR-Ras is localized 
to the non-raft membranes is due to its N-terminal transmembrane domain E1 (QI). The 
C-terminus (H-Ras 3S) of EHR-Ras cannot be post-translationally modified by addition of 
lipids and therefore cannot tether to the plasma membrane. Our results demonstrated that the 
E1 (QI) transmembrane sequence can be used to target proteins to the non-raft domains of 
the plasma membrane.   
We also demonstrated that Ext-Ras resides primarily on the lipid rafts. The only 
sequence differences between Ext-Ras and H-Ras are as that Ext-Ras has an extension of six 
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lysine residues in the C-terminus, and Ext-Ras lacks the last three amino acids of the 
‘CAAX’ farnesylation motif. Ext-Ras also keeps the cysteine previously used for farnesyl 
attachment as well as at the two natural cysteines in the H-Ras C-terminus, and therefore 
Ext-Ras is able to be palmitoylated (19). Thus, the membrane tethering of Ext-Ras is enabled 
due to its C-terminal palmitates and the added basic region. Compared with H-Ras61L, our 
data shows the microdomain localization of Ext-Ras61L is in the lipid rafts. Acylated 
(palmitoylated or myristoylated) protein motifs have been shown to favor lipid raft 
microdomains on the plasma membrane (10). However, how basic residues affect the lateral 
sequestration of plasma membrane microdomains has not been totally clarified. Peptides that 
have polylysine residues together with the farnesylated residues have been shown to 
associate with high affinity with specific anionic lipids (48). Other work has suggested that 
basic clusters on the myristoylated alanine-rich C kinase substrate (MARCKS) may attract 
lipid shells enriched in cholesterol (lipid rafts) on the cytoplasmic leaflet of the plasma 
membrane (49). We proposed that the basic residues in the Ext-Ras might contribute to raft 
localization. However, a non-palmitoylated Ext-Ras C181S/C184S/C186S mutant, which has 
the exact basic region that occurs in the normal Ext-Ras61L C-terminus, was not detected on 
the membrane fractions, but was found in the cytosolic fraction (19). Therefore, the basic 
region alone cannot support sufficient membrane interaction with lipid rafts, but can together 
with the palmitoylation sites. This is the first study to show that the C-terminal membrane 
anchor (polylysine and palmityolation residues) of Ext-Ras, preferentially targets H-Ras to 
lipid rafts.  
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The non-raft membranes allow EHR-Ras signaling, and the raft membranes allow 
Ext-Ras signaling 
Our results demonstrated that both EHR-Ras and Ext-Ras have the ability to recruit 
effectors and activate downstream signaling cascades when they are in a GTP bound state. 
EHR-Ras61L recruited Raf-1 on the plasma membrane and exhibited about one-third of the 
activation of ERK1/2 as that of H-Ras61L. EHR-Ras61L also showed limited recruitment of 
PI3kinase-p85 on the PM and demonstrated low activation in the PI3-kinase-AKT pathway. 
Ext-Ras61L recruited some PI3kinse-p85 and showed considerable activation of the 
PI3-kinase-AKT pathway, but barely recruited Raf-1 on the PM and showed low activation 
of ERK1/2.  
EHR-Ras61L, the non-raft localized H-Ras, recruits Raf-1 and activates ERK1/2 
moderately in contrast to the raft-localized Ext-Ras. Our immunofluorescence and Western 
blot data on EHR-Ras indicated that translocation of Raf-1 to the plasma membrane or the 
activation of Raf-1 (in the MAPK pathway) could be independent of lipid rafts. Lipid rafts 
are rich in cholesterol, and cyclodextrin’s ability to absorb cholesterol can therefore disrupt 
lipid rafts. Other investigators have also shown that the activation of MAPK can take place in 
the membranes that were treated with cyclodextrin, implying that the non-raft microdomains 
allow the activation of this signaling cascade (50, 51). Together with the observations of 
other non-raft located H-Ras chimera (18), our results further demonstrate that H-Ras 
activated Raf-MEK-ERK cascades exist on the bulk of the plasma membrane without lipid 
rafts.  
When Ras recruits Raf and activates its downstream MAPK signaling cascade, the 
Raf, MEK, and ERK kinases are organized in modules (52). We observed that Raf-1 
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recruitment and phosphorylation of ERK is much decreased for Ext-Ras61L, a raft localized 
Ras. The weak Raf-1 and ERK activation was also seen in other Ras constructs that were 
artificially targeted to the lipid raft microdomain using N-terminal membrane targeting 
signals (18, 33). Recently Eisenberg et al. research proposed that clustering of raft located 
proteins might limit the mobility of H-Ras and inhibit the downstream MEK/ERK signaling 
pathway (53). Further studies need to be done to explore how the signaling partners in the 
MAPK pathway are recruited in lipid rafts.  
Our results demonstrate that the raft localized H-Ras, Ext-Ras61L, showed some 
colocalization with the PI3 kinase p85 subunit and can also activate the PI3 kinase-Akt 
pathway. One class of PI3 kinases, PI3 kinase α, is composed of a catalytic subunit of 110 kd 
(p110α) and a regulatory subunit of 85 kd (p85α). The p110α subunit interacts with 
activated Ras. Because p85α and p110α form a complex in vivo and the association between 
them is very tight (54, 55), we determined the degree of interaction between Ras and PI3 
kinase-p110α by detecting the colocalization of Ras and PI3K-p85. The colocalization of 
p85-PI3K on the PM with Ext-Ras61L indicated that PI3 kinase can interact with H-Ras in a 
lipid raft environment. One product of the PI3 kinase reaction, PtdIns (3,4,5) P3, can bind to 
the pleckstrin homology domains (PH domains) of signaling proteins including AKT kinases. 
Therefore, the activation of AKT can be used to monitor PI3 kinase activity. Our finding that 
Ext-Ras61L activated the PI3 kinase-AKT pathway here in NIH 3T3 cells is supported by 
our lab’s previous results that showed Ext-Ras61L strongly activated the PI3 kinase pathway 
in the PC12 cells (25). The level of Ext-Ras activation of the PI3 kinase pathway is not the 
same in NIH 3T3 cells and PC12 cells. Why this is so is not currently known. Activation of 
AKT in rafts has also been demonstrated with a raft targeted Ras that used a N-terminal 
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myristoylation signal of LCK (18). These observations all suggested H-Ras activation of the 
PI3 kinase pathway does in fact occur in lipid rafts.  
Our findings showed that the non-raft localized H-Ras, EHR-Ras61L, co-aligned less 
with PI3 kinase on the PM than H-Ras61L and Ext-Ras61L. In the NIH 3T3 cells that 
expressed EHR-Ras61L, we also observed low AKT activation, which is an indicator of low 
PI3 kinase activity. Earlier research also showed that the PI3 kinase activity initiated by 
EHR-Ras61L was weaker than that of H-Ras61Lin 293T cells (26). The compromised AKT 
activation was also found in another non-raft targeted H-Ras that used a N-terminal 
transmembrane domain of the CD8α receptor (18). These results suggested that H-Ras-
induced PI3 kinase activation can occur within non-raft microdomains, although the degree 
of activation may be decreased.  
Thus, H-Ras signaling will still occur if H-Ras is preferentially located to the 
different plasma membrane microdomains. Furthermore, the translocation of H-Ras between 
raft and non-raft microdomains is not prerequisite for H-Ras signaling. 
Though the effector domain structures and the general orientation of Ext-Ras and 
EHR-Ras should be similar to that of natural H-Ras, their membrane anchors and the part of 
the structures that are close to the membrane targeting motif may not be exactly the same as 
those of  natural H-Ras. These features could play a role in how effectively Ras acsesses 
effectors and signaling activators. For example, a recent study pointed out a new switch 
region in the H-Ras C-terminus that includes the hypervariable region (HVR). This switch 
region influences H-Ras membrane orientation and regulates MAPK signaling (56). In 
addition, the polybasic region in Ext-Ras may enhance the interaction with the 
phosphatidylinositol (4,5)-bisphosphate PtdIns (4,5) P2 (57), which is a substrate for PI3 
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kinase, and this enhanced interaction may then increase the activation of PI3 kinase 
downstream cascades. Additional information is needed to determine whether this happens.  
Raft and non-raft located Ras variants both exhibit biological functions 
Although both the EHR and Ext proteins exhibit differences in their localization in 
either non-raft or raft microdomains, both EHR-Ras61L and Ext-Ras61L are biologically 
active. This is shown by the morphology and anchorage-independent growth (soft agar and 
focus assays) in NIH 3T3 cells, as well as by the differentiation of PC12 cells. There are 
observable biological differences between these Ras variants and H-Ras. This can be seen in 
both NIH 3T3 cells and PC12 cells. On soft agar, cells expressing EHR-Ras61L grow 
significantly slower than cells expressing H-Ras61L, and the cell clumps were significantly 
smaller than those of H-Ras61L or Ext-Ras61L. In PC12 cells, H-Ras 61L expression results 
in a few, relatively straight neurite protrusions per cell. EHR-Ras61L expression results in 
many neurite outgrowths, but the projections often took 24 hours longer to appear than those 
of cells expressing H-Ras61L. Ext-Ras61L caused a differentiated phenotype with 
exaggerated neuritic structures, with most of them exhibiting a kinked morphology, and 
Ext-Ras61L neurite growth was very fast. These differences in phenotypes may result from 
differences in the pathways related to H-Ras activation. Our findings suggest that activated 
H-Ras, whether residing in raft or non-raft microdomains, is capable of stimulating cell 
transformation. However, the different cellular phenotypes observed may result from the 
activation of different combinations of downstream signaling cascades. 
Taken together, the results show that we have successfully targeted two H-Ras 
protein variants, Ext-Ras and EHR-Ras, to localize preferentially in two different membrane 
microdomains. Our results from the investigation of Ext-Ras and EHR-Ras suggest that both 
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the non-raft and raft microdomains allow H-Ras signaling and biological function, although 
the extent of downstream signaling is not equivalent for these Ras variants: Ext-Ras61L 
activates the PI3 kinase-AKT pathway but decreases the recruitment of Raf-1, whereas 
EHR-Ras activates the MAPK pathway but limits AKT activation in NIH 3T3 cells. Thus, 
the previous models that assumed a shifting of raft to non-raft for H-Ras signaling may need 
to be modified, since such shifting may not be a prerequisite for Ras activation, signaling, 
and biological function. Additionally, we have demonstrated that the E1 (QI) transmembrane 
sequence in EHR-Ras targets Ras proteins to the non-raft domains of the plasma membrane, 
and the C-terminal membrane anchor (polybasic residues together with the palmitoylation 
sites) in Ext-Ras can target Ras to the lipid rafts. Because EHR-Ras and Ext-Ras variants can 
be successfully targeted to non-raft or raft domains, these constructs can serve as models in 
the study of Ras functioning in different microdomain localizations. 
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FIGURE LEGENDS 
FIG. 1.  Illustration of the interactions of H-Ras, Ext-Ras, and EHR-Ras with the 
plasma membrane. In this study, several Ras variants were utilized: H-RasWT, 
H-Ras61L, EHR-RasWT, EHR-Ras61L, Ext-RasWT and Ext-Ras61L. The 
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C-terminus of EHR-Ras was made from H-Ras61L-3S, which is cytosolic dues to 
three cysteines to serine substitutions, 3S (SMSSKSVLS), at the C-terminus, which 
alters or abolishes the post-translational processing and lipid modification of the 
protein. EHR-Ras also has an N-terminal IBV E1 (QI) transmembrane anchor in 
addition to its 3S mutations in the C-terminus. The linker region between the 
transmembrane domain and the Ras protein in EHR-Ras is 22-amino acids in length. 
Ext-Ras has three Cys in C-terminus, but lacks the ‘CAAX’ motif for farnesylation. 
Instead, it has a polybasic region in the C-terminus. This Ext-Ras variant can attach 
to the plasma membrane. All Ras variants were made in both a wild type (WT) and 
the oncogenic variant, which contains the point mutation Gln61 to Leu (designated 
as 61L).  
FIG. 2. EHR-Ras and Ext-Ras are located on plasma membrane. All scale bars in this 
figure = 10 µm. NIH 3T3 cells were transfected with EHR-RasWT. (A) or 
Ext-RasWT (C) DNA for 24 hours, then fixed, permeabilized, and stained with an 
H-Ras antibody then with appropriate secondary antibodies labeled with fluorescent 
probes (red). Adherent basal plasma membrane fragments from NIH 3T3 cells 
expressing EHR-Ras61L (B) or Ext-Ras61L (D) were prepared by sonication, then 
fixed and stained directly with an antibody to H-Ras and AlexaFluor-labeled 
secondary antibody (green). 
FIG. 3. Fractionation assays show EHR-Ras associates with detergent sensitive 
membrane fractions whereas Ext-Ras preferentially associates with detergent 
resistant membrane fractions. (A) Cytosolic (S) and membrane fractions from 
NIH 3T3 cells expressing EHR-RasWT or GFP-H-Ras61L protein were prepared 
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(NTX) as described under “Material and Methods” prior to the detergent treatment. 
Membrane fractions were then pretreated with 0.2% Triton X-100 for 30 min on ice 
and subjected to centrifugation to separate detergent soluble (DS) and detergent 
resistant membrane (DRM) fractions. Each fraction was acetone precipitated, 
separated by SDS-PAGE, and then subjected to immunoblotting with anti-H-Ras 
antibody to detect Ras. EHR-Ras exhibits multiple bands due to multiple 
glycosylation states for E1 (QI). An anti-caveolin-1 immunoblot identified the lipid 
raft fractions, and an anti-transferrin receptor antibody identified the non-raft 
fractions. The molecular weight of the EHR-Ras upper band is ~40 kd, and the 
molecular weight of the GFP-Ras band is 48 kd. (B) Cytosolic (S) and membrane 
fractions from Cos-1 cells expressing the Ext-Ras61L or H-Ras61L protein were 
prepared as described in “Material and Methods”. Membrane fractions were then 
pretreated with 1 % Triton X-100 for one hour on ice and then were subjected to 
centrifugation and separated as detergent soluble (DS) and detergent resistant 
membranes (DRM). Each fraction was acetone precipitated, separated by SDS-
PAGE, then immunoblotted with anti-H-Ras antibody to detect Ras. 
FIG. 4. EHR-Ras and Ext-Ras show different distributions on density gradients. (A) 
P-100 crude membrane fractions prepared from NIH 3T3 cells expressing either 
H-Ras61L or ExtRas-61L, and 293T cells expressing EHR-RasWT proteins were 
pretreated with 0.2% Triton X-100 for 30 min on ice and all extracts were subjected 
to centrifugation on detergent-free Optiprep gradients as described under "Material 
and Methods." EHR-Ras was detected in the different fractions by immunoblotting 
with an anti-H-Ras antibody. EHR-Ras displays multiple bands due to multiple 
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glycosylation states for E1 (QI). Anti-caveolin-1 immunoblotting and anti-GM1 dot 
blot identified the lipid raft fractions. The immunoblots were scanned and the band 
densities were quantified by Image J software. (B) Membrane fractions from NIH 
3T3 cells expressing either H-Ras61L or Ext-Ras61L protein were solubilized in  
1 % Triton X-100 for 30 min on ice and then were resuspended in detergent-free 
Optiprep gradients as described in "Material and Methods." The immunoblots were 
probed with anti-H-Ras antibody to identify H-Ras in the fractions. Anti-caveolin-1 
immunoblotting identified the fractions containing lipid rafts. The immunoblots 
were scanned and the band densities were quantified by Image J software. The 
distribution of Ras proteins in gradient factions was calculated. 
FIG. 5. EHR-Ras is extracted from membranes treated with 0.2% Triton, while Ext-
Ras61L is resistant to 1% Triton. All scale bars in this figure = 10 µm. (A) 
Merged images of NIH 3T3 cells co-expressing EHR-Ras61L or EHR-RasWT (red) 
with LYFP-GPI (green). Intact cells were treated with detergent-free buffer (no 
TX), permeabilized with methanol before fixation for the control groups. For the 
experimental groups, cells were treated with ice-cold 0.2% Triton X-100 (TX) for 5 
minutes to extract non-raft regions of the membrane before fixation and staining 
with antibody to H-Ras and appropriate secondary antibodies labeled with 
fluorescent probes (red). Most of the red is washed off after Triton treatment. The 
glycosylphosphatidylinositol anchored proteins (GPI) remain on the raft regions of 
the membrane. LYFP-GPI was used for co-transfection to ensure that protein 
localized to a raft domain was not removed by this treatment. (B) Adherent 
membrane fragments from sonicated NIH 3T3 cells expressing Ext-Ras61L or 
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H-Ras61L were exposed to cold 0.2% or 1%Triton X-100 for 5 min, washed, then 
fixed in paraformaldehyde and stained with H-Ras antibody then with appropriate 
secondary antibodies labeled with fluorescent probes. Ext-Ras61L is mostly retained 
on cellular membranes after Triton treatment. H-Ras61L is completely extracted 
after 1% Triton treatment. 
FIG. 6. Ext-Ras does not co-localize with caveolin on native membranes. All scale bars 
in this figure = 10 µm. Adherent membrane fragments from sonicated NIH 3T3 
cells expressing Ext-Ras61L were fixed with formaldehyde and stained directly with 
anti-H-Ras (green) and anti-caveolin-1 (red) antibodies and then with the 
appropriate fluorescent secondary antibodies. Merged image and zoomed inset show 
little overlap between Ext-Ras61L and caveolin-1. 
FIG. 7. Raf-1 co-localizes with EHR-Ras61L on the plasma membrane but not with 
Ext-Ras61L. All scale bars in this figure = 10 µm. (A) Column 1: Intact NIH 3T3 
cells stably expressing EHR-Ras61L were fixed, then EHR-Ras61L and endogenous 
Raf-1 (red) detected by appropriate primary antibodies and fluorescent antibodies, 
with vertical z-stack images of each color deconvolved. Arrows indicate the 
presence of Ras and Raf-1 on the plasma membrane. Columns 2, 3, 4: NIH 3T3 
cells were transfected with Ext-Ras61L, H-Ras61L or H-RasWT respectively. In 
column 2, after transfection with H-RasWT for 12 hours, cells were serum starved 
for 12 hours. Then the adherent membrane fragments from sonicated cells were 
labeled with anti-H-Ras antibody (green), anti-Raf-1 (red) antibody and detected 
with AlexaFluor-labeled secondary antibodies. In column 3 and 4, after 24 hours of 
transfection with H-Ras61L or Ext-Ras61L, adherent membranes fragments from 
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sonicated cells were incubated with anti-H-Ras (green), anti-Raf-1 (red) antibodies 
and detected with appropriate fluorescent secondary antibodies. (B) NIH 3T3 cells 
were co-transfected with H-RasWT and GFP-RBD (green) for 12 hours in complete 
media and then cultured in a serum-starved media for 12 hours. A 0 min sample was 
then collected. Remaining cells were stimulated with 10 ng/ml EGF for 10 min, and 
then a sample was collected. Cell samples were sonicated and the adherent 
membrane fragments from these cells were washed, fixed and labeled with H-Ras 
antibody then with appropriate fluorescent antibodies (red). 
FIG. 8. The co-localizations of EHR-Ras61L, Ext-Ras61L and H-Ras61L with p85 on 
the plasma membrane. All scale bars in this figure = 10 µm. Columns show 
images of NIH 3T3 transfected with DNA of EHR-Ras61L, Ext-Ras61L or 
H-Ras61L. After 24 hours, cells were sonicated, fixed, and then labeled. On these 
adherent membrane cell fragments, H-Ras61L, Ext-Ras61L or EHR-Ras61L was 
detected with anti-H-Ras antibody (green), while p85 was detected using anti-PI3 
kinase p85 antibody (red). Merged images and zoomed insets show co-localizations 
of Ras and their corresponding effector proteins. The extent of co-localization was 
measured using MetamorphTM software with EHR-Ras61L and p85 demonstrating 
approximately 7% co-localization; Ext-Ras61L and p85, 15%; and H-Ras61L and 
p85, 25% on the displayed and zoomed images. 
FIG. 9. Activation of effector proteins by EHR-Ras61L and Ext-Ras61L. (A) NIH 3T3 
cells stably expressing the H-Ras61L, Ext-Ras61L or EHR-Ras61L proteins were 
grown to 107 per 100 mm tissue culture plate. Cells were lysed as described on 
“Material and Methods”. Lysates from each cell line were loaded in each lane of the 
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SDS-polyacrylamide gel from the same experiment and the blot is probed with 
anti-Ras antibody and examined by immunoblotting. The bottom panel shows the 
endogenous tubulin level of each sample as a loading control. (B) Activation of 
ERK1, 2 by H-Ras61L, Ext-Ras61L or EHR-Ras61L proteins. NIH 3T3 cells stably 
expressing the indicated Ras proteins were lysed and processed as described in 
“Material and Methods”. The lysates from each cell line were loaded in each lane of 
the SDS-polyacrylamide gel. Total ERK, phospho-ERK and Ras were detected by 
immunoblotting from the same lysate for each cell line, and scanned images were 
quantified by using the Image J software. The ratio between phospho-ERK to total 
ERK was normalized for Ras levels. ERK activation level for cells stably expressing 
H-Ras61L was set to 1.00. The same calculation method was used for Ext-Ras61L 
and EHR-Ras61L experiments. The graph shows the average ± S.D. of 4 
independent experiments. (C) Activation of AKT by H-Ras61L, Ext-Ras61L or 
EHR-Ras61L proteins. NIH 3T3 cells stably expressing the indicated proteins were 
lysed as described in “Material and Methods”. The Ras expression level for each 
cell line was as shown in (A). Lysates from H-Ras61L, EHR-Ras61L and 
Ext-Ras61L were loaded in each lane of the SDS-polyacrylamide gel from the same 
experiment. Total AKT, phospho-AKT, and Ras were detected by immunoblotting 
from the same lysate for each cell line, and scanned images were quantified by 
using the Image J software. The values show the relative activation level of AKT in 
cells expressing each Ras variant, normalized for Ras levels. The AKT activation 
level for cells stably expressing H-Ras61L was set to 1.00. The graph represents the 
mean ± S.D. of 4 independent experiments. (D) Activation of JNK by H-Ras61L, 
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Ext-Ras61L or EHR-Ras61L proteins. NIH 3T3 cells stably expressing the indicated 
proteins were lysed and processed as described in “Material and Methods”. The Ras 
expression level in each cell line was shown in FIG. 10A. Lysates from each cell 
line were loaded in each lane of the SDS-polyacrylamide gel from the same 
experiment. Total JNK, phospho-JNK, and Ras were detected by immunoblotting 
from the same lysate for each cell line, and scanned images were quantified by 
using the Image J software. The ratio between phospho-JNK and total JNK was 
normalized for Ras levels. The JNK activation level for cells stably expressing 
H-Ras61L was set to 1.00. The same calculation method was used for Ext-Ras61L 
and EHR-Ras61L experiments. These values showed the ranges (mean ± S.D.) of 
two independent experiments. 
FIG. 10. Biological activity of EHR-Ras61L and Ext-Ras61L in PC12 cells. Cells after 
activation with NGF. Four days after transfection with Ext-Ras61L, GFP H-Ras 
61L, or EHR-Ras61L. PC12 cells showed a growth of neurite extension.  
FIG. 11. Growth in soft agar and loss of anchorage-dependent growth in EHR-Ras61L. 
Two examples of typical colonies expressing (A) EHR-RasWT, (B) EHR-Ras61L, 
(C) GFP-H-Ras61L, after growth in soft agar for 14 days. (D) Percentages of cells 
that showed colony growth in soft agar. Cells transfected with EHR-RasWT showed 
no colony growth (0%), whereas cells transfected with EHR-Ras61L or GFP-H-
Ras61L showed robust colony growth, 22% and 47.3%, respectively. The 
percentages of cells expressing each Ras protein are as follows: 52.9% for EHR-
RasWT, 75.4% for EHR-Ras61L and 88.9% for GFP-H-Ras61L. NIH 3T3 cells 
stably expressing EHR-WTRas, EHR-Ras61L, or GFP-H-Ras61L were plated in 
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soft agar in order to assess their ability to grow in an anchorage-independent 
manner. On the 14th day after plating, cells were counted and clusters with two or 
more cells were counted as colony growth. The graphs for EHR-RasWT and GFP-
H-Ras61L represent the mean ± S.D. for three plates from the same experiment. 
TABLE LEGENDS 
Table1. Transformation of RAT1 cells by EHR-Ras proteins. RAT1 cells were 
transfected with H-Ras61L and EHR-Ras61L DNA. Amount of DNA used varied 
from 3–100 ng/plate for H-Ras61L and 10–100 ng/plate for EHR-Ras61L. Two to 
four plates of each DNA concentration were counted. Foci of transformed cells were 
counted after 12–17 days of transfection. Data presented here show the average 
number of foci counted, normalized to 1 µg of DNA. 
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TABLES 
Table1 
Transformation of RAT1 cells by EHR-Ras proteins 
DNA transfected Average No. foci/µg 
EHR-Ras61L 1500 
H-Ras61L 2108 
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CHAPTER 4. GENERAL CONCLUSIONS 
Overview 
This dissertation describes one mechanism behind H-Ras endocytosis. This 
dissertation also describes the distribution of H-Ras on the plasma membrane microdomains 
and its subsequent activation of the signal transduction cascades. In the area of H-Ras 
endocytosis, this work provides evidence for a novel, clathrin-independent mechanism. In the 
area of H-Ras membrane microlocalization, this work provides evidence that both raft and 
non-raft microdomains serve as H-Ras signaling platforms. These discoveries expand our 
current understanding of H-Ras trafficking and localization at the sub-cellular level and thus 
provide new sites and directions for future research. 
Summary of Our Studies 
Clathrin-independent endosomes associated with Arf6 bind both active and inactive forms 
of H-Ras 
Until recently, H-Ras has been shown to be present on the vesicles that are 
characterized as endosomes in addition to some of the more traditional sub-cellular locations 
such as the plasma membrane [1, 2]. However, how H-Ras reaches the endosomes and what 
type of endosomes H-Ras binds is not fully illustrated.  
H-Ras is endocytosed through a clathrin-independent pathway 
We discovered that H-Ras traffics within the cell through a clathrin-independent 
pathway. Neither the GDP bound form nor the GTP bound form of H-Ras is co-localized 
with clathrin or EEA-1, either on the plasma membrane or in the cytosol. This indicates that 
H-Ras utilizes the clathrin-independent pathway at early and later stages of its 
internalization, and the activation of H-Ras does not change the usage of this pathway. Thus, 
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this study demonstrates a new route by which H-Ras is distributed on the endosomal 
membrane after H-Ras reaches the plasma membrane. This clathrin-independent endocytosis 
pathway may be another microenvironment that allows the interaction between H-Ras, lipids, 
and other proteins.  
H-Ras binds to the Arf6 endosomes 
The Arf6 endosomes provide a good platform for studying the H-Ras endocytosis 
pathway. Using this platform, we found that although GTP bound H-Ras is located on the 
Arf6 endosomes, the recruitment of one of the Ras effectors, Raf-1, on these endosomes is 
limited. This observation indicated that H-Ras can initiate signaling on the Arf6 endosomes 
and selectively recruits the signaling partner. This finding adds to the already complex nature 
of Ras signaling and highlights the uniqueness of the Arf6 endosomes as potential signaling 
platforms. Recent studies from Porat-Shliom et al. [3] showed that H-Ras is sequestered in 
Arf6Q67L vacuoles; the Arf6Q67L vacuoles recruit the active form of the Ras effectors ERK 
and AKT but not Rab5. Our studies, together with the work from Porat-Shliom et al. [3], 
further demonstrate that H-Ras can cooperate with Arf6 in signaling, vesicular trafficking, 
and biological functions. 
Properties of H-Ras and K-Ras proteins in endocytosis 
We observed that both H-Ras and K-Ras bind to Arf6 endosomes. K-Ras has been 
found to be released from the plasma membrane and localized to the mitochondria through 
phosphorylation of Serine 181 in its C-terminal basic region by protein kinase C [4]. In rat 
hippocampal neurons, K-Ras was found to escape from the plasma membrane and relocate to 
the Golgi apparatus though binding with the Ca2+/calmodulin at the K-Ras C-terminus upon 
glutamate stimulation [5]. This dissertation describes a new trafficking pathway in which 
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K-Ras is distributed on endosomal membranes in a different manner from those previously 
described pathways.  
My work demonstrated that both the palmitoylated Ras, H-Ras (or H-Ras tail), and 
the non-palmitoylated Ras, K-Ras (or K-Ras tail), are distributed on the Arf6 endosomes. 
This finding illustrates that the mechanism by which H-Ras and K-Ras localize on the Arf6 
endosomal membranes is different from the other recently studied de-palmitoylation/ 
re-palmitoylation mechanism [6]. In that mechanism, de-palmitoylation causes H-Ras and 
N-Ras to dissociate from the plasma membrane. Ras proteins can then be randomly captured 
at the Golgi apparatus, get re-palmitoylated, and then travel through the secretory pathway 
back to the PM. The studies described here also show that Ext-Ras, an H-Ras variant in 
which the C-terminal farnesylation motif has been replaced with multiple lysine residues, is 
not found on the Arf6 endosomes. These results indicate that the N-terminal conserved 
region of Ras does not appear to control endocytosis, but the C-terminal farnesylation motif 
might play a role in relocating H-Ras to the Arf6 endosomes. 
In this study, K-Ras was not found on the endosomal recycling center (ERC), which 
suggests that K-Ras does not reach the ERC during endocytosis. Though the mechanism 
behind K-Ras recycling has not yet been fully understood, it is possible that K-Ras may 
disassociate from the endosomes prior to reaching the ERC and perhaps traffic back to the 
PM via non-vesicular means. This study also verifies that H-Ras utilizes the perinuclear 
recycling center during endocytosis. H-Ras and K-Ras are highly homologous over the 
N-terminal 165 residues. However, the recycling of H-Ras and K-Ras exhibits an obvious 
difference. The difference between H-Ras and K-Ras during the recycling could be due to 
their last 24 C-terminal residues by several possibilities: (a) C-terminal palmitoylation may 
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be needed for Ras to distribute on the ERC, (b) the polybasic region of the C-terminus might 
prevent K-Ras from associating with the ERC, and (c) other residues in the C-terminal 
hypervariable region (HVR) might influence the association of Ras with the ERC. 
Activation of different isoforms of Ras—H-Ras, K-Ras, and N-Ras—result in various 
responses at the molecular, cellular, and even the organismal levels [7, 8]. This study helps 
us further understand that these variations may be due to the different ways these isoforms of 
Ras act in the endocytic pathways. Moreover, this study provides clues as to why their 
endocytosis and recycling mechanisms are different and could be used as a basis to study the 
trafficking of other proteins in the Ras GTPase super family. 
Concluding remarks 
This research work reveals novel trafficking pathways for H-Ras and K-Ras 
endocytosis. Together with other new findings on H-Ras localization on the ERC and on 
recycling endosomes [9], this study completes a loop describing how membrane bound 
H-Ras endocytoses and recycles back to the plasma membrane. Thus, the entire landscape of 
H-Ras trafficking outward-bound to the plasma membrane and inward-bound to the cytosol 
becomes better outlined. 
Ras proteins have essential roles in activation of their downstream signaling cascades, 
which in turn control cell proliferation, migration, survival, and differentiation [10]. 
Mutations in Ras genes can cause their related signaling network to become out of control 
and lead to the malignant growth of cells—tumors [11]. In humans, 20% of all cancers have 
been found to contain the mutations of Ras proteins [12]. Originally, the plasma membrane 
was thought to be the final destination for Ras proteins where they could produce signals. 
Studies from Porat-Shliom et al. [3] showed that activation of Ras stimulates plasma 
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membrane ruffling and macropinocytosis. They also found the active form of H-Ras can 
recruit some of its downstream effectors when trapped on Arf6Q67L vacuoles during a 
certain stage of macropinosome maturation. These findings and our work on Ras endocytosis 
and recycling provide evidence for a new platform for controlling Ras signaling level and 
signaling specificity in a spatial and temporal manner. Thus future cancer therapies will need 
to take into account the fact that Ras signaling also occurs during endocytosis.  
Arf6 protein has been shown to function in membrane trafficking, actin remodeling, 
and cellular endocytosis through the interactions with its effector proteins and membrane 
lipids [13, 14]. Arf6 protein has also been found to be involved in the invasion and metastasis 
of breast cancer cells [15]. This observation of the intracellular association of Ras proteins 
with Arf6 may lead to more insights in the study of Arf6 GTPase induced tumor invasions. 
Mutations of different Ras isoforms—H-Ras, N-Ras and K-Ras—have been found in 
different types of cancers [16]. These isoforms of Ras differ primarily in their C-terminal 
sequences. Our results illustrate that the specific amino acid sequence and lipid modifications 
in the C-terminal tails of Ras proteins control the endocytosis and trafficking of Ras proteins. 
Thus, this finding provides a basis for further studying Ras signal transduction and cancers 
caused by the mutations of these Ras proteins. 
Biological activity and signaling of two H-Ras variants designed to be preferentially “in” 
or “out” of rafts 
“Raft” and “non-raft” are two microdomains of the plasma membrane [17, 18]. H-Ras 
has been found localized on the microdomains on the plasma membrane [19–22]. However, 
whether H-Ras signals and produces biological function exclusively from a raft or non-raft 
microdomain has not been thoroughly elucidated [20, 23–26]. In order to study this, we 
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utilized two H-Ras variants (EHR-Ras and Ext-Ras) that were designed to reside in non-raft 
or raft microdomains respectively, and we found the following to be true. 
Both non-raft and raft microdomains allow H-Ras signaling 
Using subcellular fractionation assays, density gradients, immunofluorescence, and 
detergent treatment methods, we were able to show that EHR-Ras that is located on the 
plasma membrane accumulates exclusively in non-raft microdomains. Ext-Ras, which is also 
located on the plasma membrane, is found distributed predominantly in lipid raft containing 
membranes. Both EHR-Ras61L and Ext-Ras61L co-localize with their effectors, such as 
Raf-1 or PI3 kinase, on the plasma membrane and induce the signal transduction in the 
MAPK kinase, PI3 kinase-AKT and JNK pathways. These results demonstrate that both 
non-raft and raft microdomains allow H-Ras signaling. They also clarify that the 
translocations of H-Ras between these microdomains are not a prerequisite for the signaling 
initiation by H-Ras. Additionally, they indicate that membrane rafts, which serve as signaling 
platforms for many signaling proteins [27–29], also provide the necessary microenvironment 
for H-Ras signaling initiation and activation of its downstream cascades.  
We also found that the extent of downstream signaling activation in different 
signaling pathways varies between these H-Ras variants. Ext-Ras61L activates the PI3 
kinase-AKT pathway but decreases the recruitment of Raf-1, whereas EHR-Ras activates the 
MAPK pathway but limits AKT activation in NIH 3T3 cells. These results indicate that the 
membrane environment and the positions where these H-Ras variants tether may influence 
the signaling level. A recent study pointed out a new switch region in the H-Ras C-terminus 
that includes the hypervariable region (HVR). This switch region influences H-Ras 
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membrane orientation and regulates MAPK signaling [30]. Therefore, these findings further 
demonstrate the signaling complexity of H-Ras on the plasma membrane.  
Both lipid raft and non-raft microdomains allow the biological activity of H-Ras  
EHR-Ras61L and Ext-Ras61L, which are localized to non-raft or raft membrane 
microdomains respectively, cause potent transformation of NIH 3T3 cells and differentiation 
of PC12 cells. In addition, EHR-Ras61L and Ext-Ras61L cause aberrant growth 
characteristics of an oncogenic Ras protein in PC12 cells. In PC12 cells, EHR-Ras61L or 
Ext-Ras61L expression results in differentiated phenotypes with exaggerated neuritic 
structures and broad cell bodies. Therefore, they reveal that both raft and non-raft 
microdomains not only allow H-Ras signaling but also enable its biological functions.  
The N-terminus of EHR-Ras targets H-Ras to the non-raft microdomain and the C-terminus 
of Ext-Ras targets H-Ras to the membrane rafts 
Our experimental data showed that EHR-Ras and Ext-Ras localized to the non-raft 
and raft microdomains, respectively. Several other groups also made Ras chimeras that were 
designed to localize to lipid rafts: Raichu-tH [26] and LCK-Ras [31]. Raichu-tH contains an 
YFP, an H-Ras conserved region, a Ras-binding domain of Raf (RBD), and a CFP in its 
N-terminus. In the C-terminus, Raich-tH keeps the membrane anchor of H-Ras, which 
consists of the last nine amino acids. The residues that enable palmitoylation, myristoylation, 
and membrane targeting in LCK were fused to the N-terminus of a palmitoylation deficient 
H-Ras variant, H-Ras181, 184S, to generate the LCK-Ras. Compared to Raichu-tH, Ext-Ras 
displays membrane localizations exclusively on the plasma membrane, while the Raichu-tH 
shows abundant distribution on the endomembranes as well as on the plasma membrane [26]. 
Compared to LCK-Ras, Ext-Ras is tethered to the plasma membrane via its C-terminus, 
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which is closer to the tethering sequence position of H-Ras than LCK-Ras; LCK-Ras is 
tethered to the membrane by the N-terminal lipid modified residues of LCK, and the 
C-terminal farnesylated residues form H-Ras181, 184S [31]. 
These results demonstrate for the first time that the E1 (QI) transmembrane sequence 
in EHR-Ras may be used to target proteins to the non-raft domain of the plasma membrane, 
and the C-terminal membrane anchor (polybasic residues together with the palmitoylation 
sites) in Ext-Ras can target H-Ras to lipid rafts. These discoveries help us to understand what 
kind of amino acid sequence and lipid modification can be targeted to the different 
microdomains of the plasma membrane and therefore further reveal the preferences of the 
interactions between membrane lipids and specific amino acid sequences. Additionally, these 
studies also provide a basis for research on other membrane bound proteins. 
Concluding remarks 
H-Ras regulates cell growth, proliferation, and survival [10]. Mutations of H-Ras 
proteins are often found in thyroid, bladder, and kidney tumors [16]. The plasma membrane 
is a major platform where H-Ras signals and produces biological functions [32]. In this work, 
we demonstrate that both non-raft and raft microdomains support H-Ras signaling and 
induction of cell biological activity by utilizing two new H-Ras variants, EHR-Ras and 
Ext-Ras. Previous models, which assumed that shifting from raft to non-raft domains was 
required for H-Ras signaling initiation [33], may need to be modified, since such shifting is 
not a prerequisite for signaling. In summary, this work further clarifies our understanding of 
how H-Ras initiates signals and activates its downstream cascades on the plasma membrane 
microdomains and increases our knowledge of the cell membrane organization. Additionally, 
this work suggests directions and models for future research in studying how the membrane 
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lipids, proteins, and Ras membrane anchors affect Ras signaling. Finally, this research also 
provides clues for further studying of carcinogenesis caused by Ras proteins. 
Extension of Research 
In order to further study the subcellular localizations of H-Ras and the Ras signaling, 
several future research directions could be considered: 
1. How does H-Ras interact with the Arf6 endosomes? 
 a. Does any region of H-Ras other than the C-terminus affect the interaction with 
 Arf6 endosomes? 
 b. Do any intracellular molecules such as lipids or proteins affect H-Ras binding 
 to Arf6 endosomes? 
2. How does the localization of H-Ras on the Arf6 endosomes affect the signaling 
specificity of H-Ras? 
 a. Can H-Ras recruit other effector proteins at this location? 
 b. Can H-Ras interact with the scaffold proteins (i.e., KSR), GEFs, or any other
 proteins that may help or inhibit H-Ras signaling at this location? 
3. During endocytosis, how do Ras and Arf6 cooperate in signaling and biological 
activity? 
 a. Will Ras regulate the Arf6 signaling activation in this pathway? 
4. What is the detailed mechanism of K-Ras endocytosis? 
5. Does N-Ras endocytose through a clathrin-independent pathway? 
6. How are Ras downstream signaling modules (i.e., MAPK cascades) assembled in 
the non-raft and raft domains of the plasma membrane? 
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